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Abstract
Globally, at least 50 million people suffer from epilepsy and almost one third of
these do not respond to treatment with one or even multiple antiepileptic drugs
(AEDs). One of the most prominent approaches trying to explain this phenomenon
termed pharmacoresistance is the target-hypothesis. It implies that epilepsy-related
or seizure-induced alterations in the properties of the molecular targets of AEDs
occur and ultimately result in reduced drug sensitivity.
Voltage-gated sodium channels constitute one of the key targets for many AEDs
(so-called sodium channel blockers), as they are crucial for neuronal excitation and
for signal transduction in the brain. For the anticonvulsant carbamazepine but also
other older sodium channel blockers a strong reduction of efficacy in use-dependent
blocking of sodium channels and thereby reduction of repetitive neuronal firing was
shown in epileptic tissue of animal models of epilepsy as well as epilepsy patients.
While older sodium channel blockers including carbamazepine interfere with the fast
inactivation of sodium channels, the novel AEDs lacosamide and eslicarbazepine ace-
tate (via its active metabolite eslicarbazepine) were shown to modulate slow inacti-
vation of sodium channels, in contrast. Due to this unique mechanism of action both
compounds were proposed to be candidate drugs to overcome pharmacoresistance.
Using the patch-clamp technique, this thesis aimed at investigating the mecha-
nism of action and the efficacy of both substances on granule cells of the dentate
gyrus, which plays an important role in limiting the spread of epileptic seizures and
thereby preventing temporal lobe seizures from generalizing. Since previous studies
were mostly performed on physiologically different cultured cell lines, here, multiple
aspects of the still not completely understood slow inactivation of sodium channels
in dentate granule cells were in the focus of investigations. Furthermore, in order
to identify potential reductions in efficacy or changes in the mechanism of action of
lacosamide and eslicarbazepine, comparisons between healthy and epileptic tissue
were made using the pilocarpine model of epilepsy. Identical experiments were also
conducted in human epileptic brain tissue that was provided after surgical removal
of the epileptic foci of treatment resistant epilepsy patients.
We could show that both substances exert potent efficacy on the slow sodium
channel inactivation, particularly on the voltage dependence of slow inactivation
(implied by a strong hyperpolarizing shift of the inactivation curve) also in dentate
granule cells. Much less pronounced effects on sodium channel fast inactivation pro-
cesses were demonstrated for eslicarbazepine in an earlier study and for lacosamide
within this thesis. These effects appear to be negligible when compared to the promi-
nent shifts of the voltage dependence of slow inactivation, however. Interestingly,
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all of the reported effects were not limited to healthy dentate granule cells but could
also be replicated in rat and human epileptic granule cells in unaltered magnitude.
As described for lacosamide within this work and for eslicarbazepine in an earlier
study, the observed effects on the slow inactivation of sodium channels translate into
inhibition of action potential firing of dentate granule cells in response to prolonged
depolarization – again without differences between epileptic and nonepileptic cells.
Subsequent analyses of the action potential firing behavior during application of
lacosamide revealed that the effects on slow inactivation processes translate into
systematic changes in the action potential waveform that further increase with the
duration of depolarization.
To sum up, lacosamide as well as eslicarbazepine show relatively small effects on
fast inactivation processes while strongly modulating the slow inactivation of sodium
channels and its voltage dependence. This is reflected by a reduction of the granule
cell firing behavior. For all of the effects described, no differences between granule
cells of epileptic and nonepileptic origin were observed. On the basis of these results
it can be concluded that both of the investigated substances have the potential to
overcome the resistance mechanism described for carbamazepine and other sodium
channel blockers, at least in the light of the target-hypothesis.
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Zusammenfassung
Knapp ein Drittel der weltweit mindestens 50 Millionen Menschen, die an Epilepsie
leiden, spricht nicht auf die Behandlung mit einem oder sogar Kombinationsbe-
handlung mit mehreren Antiepileptika an. Die Zielstrukturen-Hypothese ist eine
der prominentesten Hypothesen, die versucht dieses Pha¨nomen, das als Pharmako-
resistenz bezeichnet wird, zu erkla¨ren. Sie besagt, dass im Verlauf der Epilepsie oder
infolge von epileptischen Anfa¨llen eine Vera¨nderung der Eigenschaften molekularer
Zielstrukturen, an denen die Antiepileptika ihre Wirkung entfalten, stattfindet. Dies
fu¨hrt schlussendlich zu einer Reduktion der Medikamentensensitivita¨t.
Spannungsabha¨ngige Natriumkana¨le stellen eine sehr wichtige Zielstruktur fu¨r
viele Antiepileptika (sog. Natriumkanalblocker) dar, da sie fu¨r die Erregung von
Nervenzellen und fu¨r die Signalweiterleitung im Gehirn kritisch sind. Fu¨r das
Antiepileptikum Carbamazepin aber auch andere a¨ltere Natriumkanalblocker konnte
in verschiedenen Tiermodellen der Epilepsie aber auch in Hirngewebe von Epilep-
siepatienten eine stark verminderte Effektivita¨t bei der Blockade von Natriumkana¨len
und der daraus resultierenden Reduktion von repetitivem Feuerverhalten von Ner-
venzellen gezeigt werden. Im Gegensatz zu allen anderen Natriumkanalblockern
modulieren die relativ neuen Antiepileptika Lacosamid sowie Eslicarbazepinacetat
(u¨ber seinen aktiven Wirkstoff Eslicarbazepin) nicht die schnelle sondern die langsame
Inaktivierung von Natriumkana¨len. Aufgrund dieser besonderen Wirkweise wurde
von beiden Substanzen erwartet, dass sie Pharmakoresistenzmechanismen potenziell
u¨berwinden ko¨nnen.
Die Wirkweise und Effektivita¨t beider Substanzen wurde im Rahmen dieser Ar-
beit unter Verwendung der Patch-Clamp Technik an Ko¨rnerzellen des Gyrus Den-
tatus, dem eine wichtige Funktion in der Verhinderung der Ausbreitung epilep-
tischer Anfa¨lle mit Ursprung im Temporallappen des Gehirns zugesprochen wird,
untersucht. Da fru¨here Studien weitestgehend an physiologisch andersartigen Zell-
kulturlinien durchgefu¨hrt wurden, wurden im Rahmen dieser Arbeit verschiedene
Parameter der noch nicht vollsta¨ndig verstandenen langsamen Inaktivierung von Na-
triumkana¨len in Ko¨rnerzellen des Gyrus Dentatus untersucht. Daru¨ber hinaus wurde
die Wirkweise und die Effektivita¨t von Lacosamid und Eslicarbazepin zwischen Kon-
trollgewebe und epileptischem Gewebe im Tiermodell verglichen, um mo¨gliche Re-
duktionen der Effektivita¨t oder Vera¨nderungen im Wirkmechanismus zu erkennen.
Identische Untersuchungen wurden ebenfalls in epileptischem humanem Hirngewebe,
das infolge der operativen Entfernung des Epilepsieherdes behandlungsresistenter
Patienten bereitgestellt wurde, durchgefu¨hrt.
Dabei konnte gezeigt werden dass beide Substanzen auch in Ko¨rnerzellen deut-
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liche Effekte auf die langsame Inaktivierung von Natriumkana¨len und hier beson-
ders auf deren Spannungsabha¨ngigkeit zeigen, zu erkennen an einer deutlichen Ver-
schiebung der Inaktivierungskurve in Richtung hyperpolarisierter Membranpoten-
tiale. Deutlich kleinere Effekte auf die schnelle Inaktivierung von Natriumkana¨len
wurden fu¨r Eslicarbazepin bereits im Vorfeld dieser Arbeit beschrieben und fu¨r La-
cosamid im Rahmen dieser Arbeit aufgezeigt. Diese Effekte fallen jedoch im Ver-
gleich zu den starken Effekten auf die Spannungsabha¨ngigkeit der langsamen Inak-
tivierung vernachla¨ssigbar klein aus. Interessanterweise sind sa¨mtliche beschriebe-
nen Effekte nicht nur in Kontrollgewebe beobachtet worden, sonden konnten in
Ko¨rnerzellen epileptischer Ratten und Epilepsiepatienten ebenso in unvera¨nderter
Gro¨ße nachgewiesen werden.
Diese Effekte auf die langsame Inaktivierung von Natriumkana¨len spiegeln sich
in einer Reduktion des Feuerns repetitiver Aktionspotentiale der Ko¨rnerzellen in-
folge la¨ngerer Depolarisation wieder, wie fu¨r Lacosamid im Rahmen dieser Arbeit
und fu¨r Eslicarbazepin in einer fru¨heren Studie ebenfalls in epileptischem und Kon-
trollgewebe unvera¨ndert beobachtet werden konnte. Weitere Analysen des Feuerver-
haltens wa¨hrend der Applikation von Lacosamid legen nahe, dass sich die Effekte
auf die langsame Inaktivierung in einer systematischen A¨nderung der Aktionspoten-
tialeigenschaften niederschlagen, welche mit der Dauer der Depolarisation zunimmt.
Zusammenfassend la¨sst sich sagen, dass sowohl Lacosamid als auch Eslicar-
bazepin vergleichsweise kleine Effekte auf schnelle Inaktivierungsprozesse bei vor-
wiegender Modulation der langsamen Inaktivierung von Natriumkana¨len und hier
besonders deren Spannungsabha¨ngigkeit zeigen, was sich in einer Reduktion im
Feuerverhalten der Ko¨rnerzellen wiederspiegelt. Fu¨r sa¨mtliche der untersuchten
Effekte konnten keine Unterschiede zwischen Zellen epileptischem und nichtepilep-
tischem Ursprungs beobachtet werden. Anhand dieser Ergebnisse la¨sst sich festhal-
ten, dass beide Substanzen, zumindest im Lichte der Zielstrukturen-Hypothese, das
Potenzial haben, den fu¨r Carbamazepin und weitere Natriumkanalblocker beschriebe-
nen Resistenzmechanismus zu u¨berwinden.
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Introduction 1.1 Epilepsy
1 Introduction
1.1 Epilepsy
Neuronal disorders affect millions of people all over the world. Epilepsy is one of
the most common neurological disorders, only being surpassed by migraine, stroke
and Alzheimer’s disease (Hirtz et al., 2007). At least 50 million people worldwide
suffer from epilepsy (World Health Organization, 2017). Estimations based on meta-
analyses, however, indicate that this number might be substantially higher, with
both prevalence as well as incidence of epilepsy in developing countries being about
twice as high as in developed countries (Ngugi et al., 2010, 2011).
Epilepsy is a complex neurological disorder characterized by the occurrence of
epileptic seizures or even the possibility of future seizures after a first seizing event
(Fisher et al., 2014). Seizures are transiently occurring signs or symptoms caused by
abnormal excessive or synchronous neuronal activity within the brain (Fisher et al.,
2005). They may differ in their location of onset, spread, severity and frequency
and can be classified as seizures with focal, generalized or unknown onset (Fisher
et al., 2017). Focal seizures originate within specific areas of a single hemisphere
and can spread locally within neuronal networks of one hemisphere of the brain
as well as extend bilaterally. This kind of seizure may impair consciousness or
awareness. Generalized seizures, in contrast, affect both hemispheres already at
onset and impair consciousness. Seizures can be accompanied by motor or nonmotor
onset-characteristics (Fisher et al., 2017). Seizure frequency can vary from less than
one per year to several per day (Gasparini et al., 2016).
The first and most common step in the treatment of epilepsy is therapy with
anticonvulsants, also called antiepileptic drugs (AEDs) (chapter 1.5). Currently
available treatment is symptomatic and not curative (Caccamo et al., 2016; Pitka¨nen
and Lukasiuk, 2011) and results in long-term seizure freedom in only around two
thirds of patients (Annegers et al., 1979; Kwan and Brodie, 2000; Sillanpa¨a¨ et al.,
1998). Patients which continue to have seizures despite being treated with two
appropriately chosen and tolerated AEDs are considered pharmacoresistant (Kwan
et al., 2010). In an attempt to achieve seizure freedom, alternative and usually more
invasive approaches like resection of the brain areas involved in seizure generation
are performed in these patients (Kwan et al., 2011; Schuele and Lu¨ders, 2008; Surges
and Elger, 2013).
Similar to the large variability in seizures, epilepsy itself can be highly variable
in terms of etiology, comorbidities and severity in each affected individual and can
be considered a spectrum of disorders rather than a single disorder (Jensen, 2011;
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Scheffer et al., 2017).
1.1.1 Temporal lobe epilepsy
According to older classifications, many epilepsies were categorized – based on the
localization of seizure origin instead of their cause – into temporal, frontal, parietal,
and occipital lobe epilepsies (Roger et al., 1989). Temporal lobe epilepsy (TLE) is
the most common type of focal epilepsy and frequently associated with pharmacore-
sistance (Hauser and Kurland, 1975; Semah et al., 1998). For the majority of TLE
patients the epileptic seizures originate in the limbic structures of the temporal lobe
such as the amygdala or the hippocampal formation, referred to as mesial temporal
lobe epilepsy (mTLE). A smaller number of patients suffer from lateral temporal
lobe epilepsy (lTLE) where seizures emerge in neocortical areas of the temporal lobe
(Dupont et al., 1999).
The most commonly observed change in brains of mTLE patients is a neu-
ropathological phenomenon called hippocampal sclerosis, characterized by neuronal
loss in specific areas of the hippocampal formation (Blu¨mcke et al., 2013; Curia
et al., 2014, chapter 1.4). Hippocampal sclerosis can also be found in numerous
animal models of epilepsy, both naturally occuring and induced (Curia et al., 2014;
Kuwabara et al., 2010; Polli et al., 2014; Schmied et al., 2008; Wagner et al., 2014;
see chapter 1.3).
1.2 The hippocampus
The hippocampal formation, frequently referred to as ’the hippocampus’, is part of
the limbic system and located in the temoral lobe of the mammalian brain (Amaral
and Lavenex, 2007; Squire et al., 2004). It is involved in many functions (Morris,
2007) but most prominently associated with spatial cognition (Hartley et al., 2014;
O’Keefe and Dostrovsky, 1971) and declarative memory (Squire, 1992; Squire et al.,
2004). The dorsal and ventral portions of the rodent hippocampus or the poste-
rior and anterior hippocampus in primates, respectively, have been associated with
distinct functions, input and output connectivity to other brain areas, as well as
molecular domains (Fanselow and Dong, 2010). The hippocampal formation con-
sists of the three-layered dentate gyrus (DG), hippocampus proper (also referred
to as Ammon’s horn (CA, from latin cornu ammonis)), and subiculum (van Strien
et al., 2009) and in a less strict sense also comprises the entorhinal and subicular
cortices (Amaral and Lavenex, 2007). The DG and CA regions present interlocked
cell layers (see figure 1) which contain the excitatory principal neurons of the hip-
pocampal formation: The hippocampus proper is composed of areas CA3, CA1 and
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the intercalated, relatiely narrow CA2 region which harbor pyramidal cells (Amaral
and Lavenex, 2007) and the DG contains multiple rows of densely packed granule
cells (Amaral et al., 2007, see chapter 1.2.1).
The entorhinal cortex (EC) connects the neocortex with the hippocampal forma-
tion and represents its main input and output structure (Amaral and Lavenex, 2007;
Witter et al., 2017). Information is propagated through the hippocampal circuitry
in many different ways: EC layer II neurons project to the granule cells of the DG
through the perforant pathway, which in turn project to pyramidal neurons of area
CA3 of the hippocampus proper via mossy fibers. These CA3 pyramidal neurons
then project on to the smaller CA1 pyramidal neurons of the ipsi- and contralat-
eral hemisphere through Schaffer collaterals and commissural fibers, respectively
(Amaral and Lavenex, 2007; Hartley et al., 2014). The classic understanding of this
pathway comprises only three synapses (EC→ DG, DG→ CA3, CA3→ CA1) and
was therefore named trisynaptic pathway. Due to the finding of projections from
CA1 to the subiculum and on to the EC the classic trisynaptic loop can be seen as
a part of a more complex polysynaptic pathway (Amaral and Lavenex, 2007; van
Strien et al., 2009).
In addition to the polysynaptic pathway, multiple subfields of the hippocampal
formation are also interconnected by less prominent projections, e.g. areas CA3,
CA1 and the subiculum receive direct monosynaptic inputs from EC layer II and III
via the perforant pathway and the temporoammonic pathway, respectively (Amaral
and Lavenex, 2007; Hartley et al., 2014). In recent years, alternative connectivity
with involvement of the narrow CA2 area in direct as well as polysynaptic pathways
have been described (Chevaleyre and Siegelbaum, 2010; Kohara et al., 2014). With
ongoing research and further advances in techniques and methods the current view
on hippocampal circuitry might evolve even further.
1.2.1 Function and organization of the dentate gyrus
Similar to the hippocampal formation, the DG itself is involved in multiple functions
that again differ between dorsal and ventral portions (Kesner, 2017). The DG seems
to be particularly important for pattern separation, i.e. transforming similar input
patterns into more dissimilar output patterns to disambiguate quite similar contexts
(Leutgeb et al., 2007). Furthermore, the DG is considered as a gate or filter, limiting
excitatory input from the entorhinal cortex to the hippocampus (Heinemann et al.,
1991; Hsu, 2007; Stringer and Lothman, 1992). Since epileptiform activity was
shown to pass the DG and spread to the rest of the hippocampal formation and
from there to other areas of the brain more easily under epileptic conditions, the
3
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Figure 1: Overview of human and rat hippocampal formations. Schematic
illustrations of the structure of hippocampal principal cell layers of a human (A)
and a rat hippocampal formation (B) as seen on cross-sections. Hil = hilus, Sub
= subiculum, scale bars = 1000 µm for drawings as well as photographs. The DG
plays a key role in limiting the input to downstream regions during normal but also
pathologic activity. Photographic insets in (A) demonstrate hippocampal sclerosis
type 1 with well recognisable neuronal loss in areas CA1 and the hilus but not areas
CA2, CA3 and the subiculum in epileptic (right photograph) compared to nonepilep-
tic (left photograph) human specimen. Hematoxylin and eosin stainings of human
hippocampal slices. Insets in (B) illustrate mossy fiber sprouting in brain slices of
pilocarpine-treated (right photograph) but not sham-injected rats (left photograph).
The zinc-containing mossy fibers are visualized in black by Timm’s staining method
and are counterstained with toluidine blue. Schematics redrawn after Blu¨mcke et
al., 2013 and Paxinos and Watson, 2009; photographic insets kindly provided by
Albert Becker and Margit Reitze.
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DG is of particular importance and interest in TLE (Behr et al., 1998; Collins et al.,
1983).
The DG comprises three layers that form a curved structure and bend around
or cap the CA3 region: The the molecular layer, the granule cell layer, and the
polymorphic layer, also called hilus (Amaral et al., 2007; figure 1). The molecular
layer is located most distal to the CA3, adjacent to the hippocampal fissure and
mostly free of cell somata. It contains a low number of interneurons and other
neurons (Han et al., 1993; Sancho-Bielsa et al., 2012; Soriano and Frotscher, 1989;
Williams et al., 2007) as well as the dendrites of the dentate granule cells and fibers
projecting to and through the DG, mostly the perforant path axons (Amaral et al.,
2007; Scharfman, 2016).
The granule cell layer constitutes the middle layer of the DG and comprises pre-
dominantly granule cells, the principal cells of the DG, along with low numbers of
axo-axonic cells and pyramidal basket cells (Amaral and Lavenex, 2007; Scharfman,
2016). Those perisomatic-targeting cells are inhibitory interneurons located at the
border to the hilus and involved in feedforward inhibition as well as feedback inhi-
bition (Acsa´dy et al., 1998; Scharfman, 2016; Zipp et al., 1989). Notably, the DG
is one of the few areas of the brain where adult neurogenesis occurs (Altman and
Das, 1965; Eriksson et al., 1998) in addition the olfactory bulb and the striatum
(Bergmann et al., 2012; Ernst et al., 2014). Dentate granule cells are continuously
renewed throughout life (Bayer, 1982; Cameron and Mckay, 2001; Spalding et al.,
2013) by stem cells located at the border of the granule cell layer and the hilus, the
so-called subgranular zone (Palmer et al., 1997).
The hilus represents the deepest of the three layers and comprises many different
cell types. In addition to the mossy fibers spanning the hilus and other fusiform
neurons, mossy cells are the most common neurons found in the hilar region (Ama-
ral, 1978; Han et al., 1993; Scharfman, 2016). The glutamatergic mossy cells can
either excite GCs directly or inhibit them via interneurons. Mossy cells that give
almost simultaneous input to granule cells as the perforant path are involved in
translamellar potentiation which is believed to be important for pattern separation
(Hsu, 2007) whereas mossy cells targeting interneurons potentially contribute to
feedback inhibition (Scharfman, 2016).
1.2.2 Granule cells of the dentate gyrus
The DG consists of around 1.2 million granule cells (GCs) in the adult rat brain
and about 15 million in adult human brains (both unilaterally; Bayer, 1982; West
et al., 1991; West and Gundersen, 1990). Single GCs of rodents and primates
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appear relatively similar in size and morphology. Rat GCs have small roundish to
ovoid somata with an average size of 10×18 µm (Claiborne et al., 1990). Similar
but more variable dimensions were reported for primate GCs includng humans GCs
(de Ruiter and Uylings, 1987; Scheibel et al., 1974; Seress and Frotscher, 1990).
Even after a trituration process, acutely isolated CGs can still be identified by their
somatic morphology in the absence of most of the axonal and dendritic processes
(Beck et al., 1997a; Mody et al., 1989).
The GC apical dendrites extend into the molecular layer in a cone shaped manner
where they synapse with lateral and medial perforant path axons, hilar interneurons
as well as other intra- and extrahippocampal neurons (Amaral and Lavenex, 2007;
Scharfman, 2016). In the rat, GCs situated in the suprapyramidal blade (located
between areas CA3 and CA1) or infrapyramidal blade (located on the opposite
side) of the DG display mostly differences in the architecture and spread of the
dendrites (Claiborne et al., 1990). Primate GCs however are more variable in terms
of dendritic arborization, density of spines on the dendrites and even soma size
(Seress and Frotscher, 1990). The most prominent difference between rodent and
primate GCs is the presence of basal dendrites which are virtually absent in healthy
rodents but present in more than 20% of healthy human GCs (Lim et al., 1997;
Ribak et al., 2000; Seress and Mrzljak, 1987).
The axons of the granule cells – the mossy fibers – project through the hilus to
the CA3 where they terminate in large boutons that synapse with the the dendrites
of CA3 pyramidal neurons. In the hilus the mossy fiber boutons make contact with
hilar mossy cell dendrites but also collateralize and target interneuronal dendrites
located within the hilus and the granule cell layer (Amaral and Lavenex, 2007; Lim
et al., 1997). The mossy fibers are glutamatergic, but also contain and are able to
release γ-aminobutyric acid (GABA), ATP, dynorphin, and zinc upon stimulation
(Chavkin et al., 1983; Howell et al., 1984; Terrian et al., 1989; Terrian et al., 1988;
Walker et al., 2002).
In comparison to other neurons, many GCs have a highly hyperpolarized resting
membrane potential around -80 mV or even lower, both in vivo and in vitro (Pent-
tonen et al., 1997; Spruston and Johnston, 1992; Staley et al., 1992) as well as a
relatively high threshold for generation of action potentials around -49 mV (Staley
et al., 1992). These properties as well as the strong control of feedforward and feed-
back inhibition possibly result in a low spontaneous activity with firing rates around
0.1 Hz in behaving animals (Jung and McNaughton, 1993; Penttonen et al., 1997).
In response to current injections, GCs show adaptation of the frequency of repetitive
action potentials, which in turn are characterized by afterhyperpolarizations (Pent-
tonen et al., 1997; Staley et al., 1992). The majority of those properties were found
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to be similar in GCs recorded from animal and human hippocampal slices (Isokawa
et al., 1991; Williamson et al., 1993). Adult born GCs, however, differ substantially
in many aspects from the mature GCs described above. They are characterized by
higher input resistance, more depolarized resting membrane potentials, and generate
single or rudimentary action potentials of lower amplitude (Liu et al., 1996; Pedroni
et al., 2014; Staley et al., 1992). They further possess smaller somata, incomplete
dendritic arborization and tend to be GABAergic (Cabezas et al., 2013; Liu et al.,
1996). Over several weeks, these characteristics gradually change and match those of
mature GCs at the end of their maturation process (Ambrogini et al., 2004; Espo´sito
et al., 2005). Mature and immature GCs also differ in the expression of molecular
markers, such as calcium binding proteins (Brandt et al., 2003; Brown et al., 2003;
Overstreet et al., 2004). Prox1, however, is a molecular marker which is expressed
in the entire GC lineage (Iwano et al., 2012; Liu et al., 2000).
GCs are not exclusively located within the granule cell layer. If located within
the hilus, they are termed ectopic GCs (Gaarskjaer and Laurberg, 1983). Those
cells usually display similar electrophysiological properties and connectivity as nor-
mal GCs from the principal cell layer (Scharfman et al., 2003; Scharfman et al.,
2000). In contrast, Prox1-expressing cells with differences in soma shape, dendritic
arborization, axon collateral targets and in electrophysiology were found in the in-
ner molecular layer and called semilunar GCs (Gupta et al., 2012; Larimer and
Strowbridge, 2010; Williams et al., 2007).
GCs express different voltage-gated ion channels in their membranes. Various
subforms of voltage-gated potassium, sodium, and calcium channels can be found
throughout all compartments of the granule neurons, however, they show distinct
expression patterns in different subcellular localizations (Vacher et al., 2008). A
subset of those channels is enriched in the axon initial segment, located in close
proximity to the soma (King et al., 2014; Schmidt-Hieber and Bischofberger, 2010;
Vacher et al., 2008). Since the description of an enzymatic approach to generate
isolated dentate GCs (Mody et al., 1989) the properties of different voltage gated
potassium, calcium and sodium currents have been described in rat (Beck et al.,
1992; Ellerkmann et al., 2003; Ketelaars et al., 2001; Ko¨hr and Mody, 1991) and
human GCs (Beck et al., 1997a,b; Reckziegel et al., 1998).
1.3 Animal models of epilepsy
During the development and research of novel AEDs, numerous animal models mim-
icking specific features of human epilepsy are used. Models for acute or chronic in-
duced seizures, models for epilepsies other than TLE and models of chronic epilepsy
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with spontaneous recurrent seizures that mimick a subset of the pathophysiological
conditions found in human TLE are widely used (Lo¨scher, 2011). Seizures alone can
be evoked by electrical stimulation (e.g. maximal electroshock seizure (MES) test)
or by injection of convulsant chemicals (e.g. pentylenetetrazole, PTZ seizure test).
Those acute seizure models are mainly used during screening of substances acting
as potential new AEDs (Lo¨scher, 2011). Other approaches such as repeated electri-
cal stimulation of limbic structures of the brain (kindling) or electrical or chemical
induction of a status epilepticus (SE) are used to generate animals that display
chronic or spontaneous recurrent seizures and may be used for further characterisa-
tion of screened compounds or for studies of epileptogenesis or pharmacoresistance
(Kandratavicius et al., 2014; Lo¨scher, 2011). In addition to the seizures, those ani-
mal models display similar patterns of neuronal loss and mimic the most striking
pathophysiological features of human TLE (Curia et al., 2008; Sutula et al., 1994,
see chapter 1.4). However, even between similar animal models the temporal profile
and magnitude of neuropathological alterations can differ (Covolan and Mello, 2000;
Kandratavicius et al., 2014; Morrisett et al., 1987).
1.3.1 The pilocarpine model of temporal lobe epilepsy
Whereas in human TLE patients epilepsy may be caused by brain malformations,
infections, diseases or be influenced by genetic factors, one of the most common ways
to induce SE in laboratory rodents and thereby generate epileptic animals that suffer
from spontaneous recurrent seizures is the administration of the chemoconvulsant
pilocarpine (Cavalheiro et al., 1991; Turski et al., 1983).
Injection of the muscarinic acetylcholine receptor agonist pilocarpine, either sys-
temically or even directly into the brain, causes an imbalance between neuronal
inhibition and excitation that results in increasingly stronger seizure activity which
builds up into a SE (Priel and Albuquerque, 2002; Racine, 1972; Turski et al.,
1983). To avoid unwanted peripheral cholinergic stimulation (piloerection, sali-
vation, tremor, chromodacryorrhea and diarrhea) after pilocarpine-injection and
restrict the effects to the brain, blood-brain barrier impermeable cholinergic an-
tagonists (e.g. methyl-scopolamine) are frequently injected before application of
pilocarpine (Clifford et al., 1987). This so-called acute period (SE) is followed by an
epoch with reduced or predominantly nonconvulsive seizure activity (Goffin et al.,
2007; Mazzuferi et al., 2012; Pitsch et al., 2017). During this often termed latent or
silent period, rodents are believed to develop and show a similar pathophysiological
changes as seen in human TLE (see chapter 1.4) thus this animal model is often
used to mimic TLE and investigate its mechanisms and treatment (Curia et al.,
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2008). Finally, during the chronic period higher numbers of behaviorally detectable
spontaneous recurrent seizures – as observed in TLE patients – emerge.
One feature of the pilocarpine model that distinguishes it from many other animal
models is the development of comparatively strong extrahippocampal or extratem-
poral damage and loss of neurons e.g. in cortical areas which can also be found
in epilepsy patients (Covolan and Mello, 2000; Marsh et al., 1997; Sanabria et al.,
2002). In the pilocarpine model of epilepsy, just like in other animal models, there
are groups of animals that respond well to AEDs, as well as groups of animals that
do respond in a variable manner or not at all to certain AEDs (Glien et al., 2002;
Lo¨scher and Rundfeldt, 1991). Similarly, a high inter-individual and even intra-
individual variability is also an issue in human epilepsy and requires individually
monitored and optimized AED schedules (Patsalos et al., 2008).
1.4 Changes in the epileptic hippocampus, dentate gyrus
and granule cells
In many cases of TLE insults to the brain, often in early childhood, were reported
and considered a possible starting point of a latent or silent period of epileptogenesis
that finally leads to epilepsy (Mathern et al., 2002a). These initial precipitating in-
juries can range from head trauma and tumors over infectious or hypoxic conditions
of the brain to febrile seizures or status epilepticus (Curia et al., 2014; Hauser et al.,
1996; Mathern et al., 2002a).
In the epileptic brain, numerous changes are observed following epileptogenesis
or SE and some alterations follow even single seizures (Parent et al., 1997; Wehner
and Lu¨ders, 2008). It is important to mention, however, that epileptogenesis can
also occur without obvoius lesions, neuronal loss and network reorganization (Marg-
erison and Corsellis, 1966; Zhang et al., 2002). The most obvious changes found
in epileptic patients and animal models are volumetric reductions of hippocampal
as well as extrahippocampal structures and thereby increased ventricle sizes (Cook
et al., 1992; Marsh et al., 1997; Perez et al., 1985; Persinger et al., 1998; Polli et al.,
2014; Sanabria et al., 2002). Hippocampal sclerosis is the most commonly observed
pathologic condition and characterized by gliosis and severe loss of neurons in single
or multiple subfields of the hippocampal formation, mainly in areas CA1 and the
hilus (Blu¨mcke et al., 2013; Margerison and Corsellis, 1966; see figure 1A). Cell
loss was reported for mossy cells and different inhibitory interneurons of the hilar
region and the surviving cells show aberrant morphology and synaptic connections
(de Lanerolle et al., 1989; Maglo´czky et al., 2000; Sloviter et al., 2003). Dentate
GCs are also subject to multiple changes. Neurogenesis of GCs is altered following
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induced seizures and during epilepsy (Crespel et al., 2005; Mathern et al., 2002b;
Parent et al., 1997). An increasing number of the newly born granule cells integrate
aberrantly outside the GC layer and are found in the hilus and the molecular layer
(Crespel et al., 2005; Parent et al., 1997; Scharfman et al., 2000). This broadening
of the cell layer is termed granule cell dispersion and may be associated with loss
of GCs or not (Houser, 1990). Compared to healthy brains, basal dendrites are in-
duced in 5% of epileptic rodent GCs and in more than 40% of cells in TLE patients
(see chapter 1.2.2; Ribak et al., 2000; Scheibel et al., 1974; von Campe et al., 1997)
accompanied by swelling or shrinkage of dendrites and a general loss or reduction
of dendritic spines (Scheibel et al., 1974). Degenerating nerve terminals as well as
sprouting of mossy fibers, i. e. a reorganization of the GC axons that aberrantly
terminate on other GCs within the principal cell layer and the molecular layer are
frequent findings in epileptic tissue (Houser et al., 1990; Parent et al., 1999; Scheibel
et al., 1974; Tauck and Nadler, 1985; see figure 1B).
In summary, loss of inhibitory interneurons and mossy cells together with in-
creased and aberrant recurrent excitatory connections and neurogenesis cause chan-
ges in the excitation-inhibition balance and may result in reverbatory networks that
are able to initiate unprovoked seizures on their own (Jinde et al., 2013; Kobayashi
and Buckmaster, 2003; Ribak et al., 2000; Spampanato and Dudek, 2017). At least
some of the alterations described so far may act as compensatory mechanisms in an
attempt to restore excitation and inhibition to levels found in healthy brains.
1.4.1 Pharmacoresistance
In addition to the cellular and structural pathological alterations that make the
hippocampus hyperexcitable, there are further changes that occur during epilepto-
genesis. Numerous hypotheses were prepared trying to explain why AEDs lose their
efficacy in pharmacoresistant epilepsy patients or model animals. Whereas many
approaches to characterize the occurrence of pharmacoresistance imply alterations
in the severity of the resistance with time, it has been further suggested that pa-
tients might be aleady pharmacoresistant from the beginning of the disease (Berg
et al., 2006; Kwan and Brodie, 2000; Lo¨scher and Schmidt, 2006).
Genetic factors such as mutations in ion channels can not only cause cause
epilepsy, they have also been shown to affect AED efficacy and required drug dosages
(Lerche et al., 2013; Tang et al., 2017). The gene variant hypothesis of pharma-
coresistance considers genetic alterations in genes encoding ion channels as well as
AED-metabolizing enzymes as possible causes of drug resistance. In this way, the
medication itself may also contribute to the development of tolerance as a form of
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pharmacoresistance. Repeated application of AEDs over prolonged periods of time
may lead to an increase in the metabolism of the drug or to drug-induced changes
in receptor densities or sensitivity (Lo¨scher and Schmidt, 2006).
In epilepsy and especially in pharmacoresistant epilepsy the active transport or
clearance of antiepileptic and other drugs from the brain via multidrug transporters
located in the endothelial cells of the blood–brain barrier (BBB) was shown to
be altered (Rizzi et al., 2002; Volk and Lo¨scher, 2005). The BBB becomes more
permeable following SE as well as during seizures in the chronic phase of human
and experimental epilepsy which in turn results in increased expression of drug
efflux transporters as a compensatory mechanism (van Vliet et al., 2006; van Vliet
et al., 2010). In animal models of and patients with pharmacoresistant epilepsy,
P-glycoprotein (PGP) and multidrug-resistance associated proteins (MRPs) as well
as further proteins related to drug resistance in diseases other than epilepsy were
found to be overexpressed (Dixit et al., 2017; Remy and Beck, 2006; Zhang et al.,
2012). The extent to which AEDs and other substrates are transported out of the
brain can vary between different tissues in which these proteins are expressed and
even more between homologous transporters of different species, however (Baltes
et al., 2007). As this upregulation of drug efflux transporters causes decreased AED
brain but not plasma levels the so-called transporter hypothesis is considered as one
of the possible mechanisms of pharmacoresistance (Remy and Beck, 2006; Zhang et
al., 2012). Similarly, the pharmacokinetic hypothesis claims that overexpression of
drug transporters is not only limited to endothelial cells of the BBB but extends to
astrocytes, neurons and even peripheral organs such as the liver which would result
in overall low AED concentrations (Lazarowski et al., 2007; Tang et al., 2017).
Another prominent approach trying to explain why AEDs lose their efficacy in
pharmacoresistant epilepsy is the target hypothesis (Remy and Beck, 2006). Altered
expression levels of voltage-gated sodium, potassium and calcium channel subunits
along with alternative splicing of sodium channel mRNA were found following SE in
different animal models of epilepsy or in human epilepsy syndromes (Lerche et al.,
2013; Remy and Beck, 2006). Similar to voltage-gated ion channels, the expression
levels and subunit composition of neurotransmitter receptors were either found or
hypothesized to be altered in TLE patients and epilepsy models (Brooks-Kayal et
al., 1999, 1998; Mathern et al., 1997, 1998; Notenboom et al., 2005). Furthermore,
seizure-induced posttranslational modifications can induce translocation or inter-
nalization of both voltage-gated ion channels as well as neurotransmitter-receptors
and thereby alter their surface-expression (Rakhade and Jensen, 2009). As many
of those channels act as targets for (novel) AEDs (Bialer et al., 2017; Doeser et
al., 2014a; Rogawski et al., 2016) those differences in channel structure, expression
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and localization may lead to impaired AED-target binding and thereby to reduced
efficacy in pharmacoresistant patients and animal models (Remy and Beck, 2006).
1.5 Antiepileptic drugs
Antiepileptic drugs (AEDs) mean to suppress the occurrence of seizures and are
therefore also referred to as antiseizure drugs or anticonvulsants, however, many
AEDs are also used in neurological disorders other than epilepsy (Landmark, 2008;
Rogawski et al., 2016). Some AEDs show additional neuroprotective properties
(Caccamo et al., 2016; Landmark, 2008; Licko et al., 2013) and only recently de-
veloped drugs seem to address the long demanded requirements of having disease
modifying or antiepileptogenic properties (Doeser et al., 2014a). Different AEDs
mediate their effects on different groups of targets which include voltage-gated ion
channels but also neurotransmitter receptors and other synaptic proteins involved
in neurotransmitter release and trafficking thereby altering and ideally restoring ex-
citation or inhibition towards more balanced levels as found in nonepileptic, healthy
brains or reducing the intrinsic excitability of neurons (Landmark, 2008; Rogawski
et al., 2016). At least seven of the more than twenty currently available AEDs
block voltage-gated sodium channels (VGSCs) as their main mechanism of action
and further AEDs with multiple modes of action affect VGSCs along other or yet
unidentified main targets (Brodie, 2017).
1.5.1 Voltage-gated sodium channels as antiepileptic drug targets
VGSCs are bell-shaped transmembrane proteins that form a cation-conducting pore
in the cell membrane of neurons and other excitable cells and are crucial for the
initiation and propagation of action potentials and the intrinsic excitability of neu-
rons (Hille, 1971, 1972; Sato et al., 2001). The Na+-conducting pore of VGSCs is
formed by a ∼260 kDa α subunit which can be associated with regulatory 30–40
kDa β subunits (see figure 2). Small differences in VGSC α isoforms result in differ-
ent properties regarding their activation and inactivation as well as their sensitivity
towards toxins and drugs (Catterall et al., 2005; Vilin and Ruben, 2001). Whereas
expression of α subunits alone is sufficient to conduct ions, the presence of one or
two β1 to β4 subunits in the VGSC complex can further modify gating properties as
well as drug and toxin sensitivity and efficacy (Catterall et al., 2005; Gilchrist et al.,
2013; Grieco et al., 2005; Lenkowski et al., 2003; Uebachs et al., 2010; Zhang et al.,
2013b). Nine isoforms of VGSC α subunits termed Nav1.1–Nav1.9 have been iden-
tified, with Nav1.1, Nav1.2, Nav1.3, and Nav1.6 being the major isoforms expressed
in the mammalian CNS (Goldin, 2001). While Nav1.1 seems to be preferentially
12
Introduction 1.5 Antiepileptic drugs
expressed on somata of hippocampal principal neurons, Nav1.2 is located rather in
processes and terminals of neurons than on their somata. High densities of Nav1.6
but also other brain soidum channels can be found clustered at the axon initial
segment. Nav1.3 is mainly expressed in the developing brain (Vacher et al., 2008).
The sodium channel α subunit is a polypeptide folding into four homologous do-
mains (termed I–IV) each of which comprises six α-helical transmembrane segments
(S1–S6; figure 2). Each of these domains comprises a voltage-sensing domain (VSD,
composed of S1–S4) and a pore-forming domain (PD, S5, S6 and their linking P-
loop). The membrane reentrant P-loops connecting segments S5 and S6 contribute
one amino acid per domain to the selectivity filter determining the selectivity for
Na+ ions (Catterall, 2017). In response to membrane depolarization, the positively
charged amino acid residues of the voltage-sensors (S4 segments) move outward and
confer an opening of the channel pore via conformational changes in the VSD and
PD thereby permitting Na+ ions to cross the membrane (Catterall and Swanson,
2015). Sustained depolarization results in fast inactivation of VGSCs after few mil-
liseconds (Hodgkin and Huxley, 1952). This is mediated by coupling movement of
one of the voltage sensors to the intracellular linker connecting domains III and
IV which acts as a blocking particle folding towards the intracellular mouth of the
channel and thereby prevents ion conduction (Ku¨hn and Greeff, 1999; Vassilev et
al., 1988). After repolarization, sodium channels recover from fast inactivation,
slightly slower but also within milliseconds (Hodgkin and Huxley, 1952). Follow-
ing prolonged depolarization or trains of action potential firing, VGSCs can enter
a distinct, slow inactivated state – either from the fast inactivated state but also
directly from open or closed channel conformations (Ellerkmann et al., 2001; Ruff,
1996). Both, entry into and recovery from slow inactivation emerge on a substan-
tially slower time scale (ranging from seconds to minutes) than entry and recovery of
fast inactivation (Ellerkmann et al., 2001; Vilin and Ruben, 2001). The mechanism
of slow sodium channel inactivation is still not completely understood. However,
structural changes in the outer pore forming loops that would cause a collapse of
the ion permeation pathway are likely involved in slow inactivation alongside with
movements of the voltage sensors and the intracellular blocking particle (Boiteux et
al., 2014a; Tikhonov and Zhorov, 2007; Vilin and Ruben, 2001; Xiong et al., 2006).
Whereas fast inactivation controls the availability of VGSCs during single action
potentials and their refractory time, slow inactivation affects membrane excitability
and properties of multiple action potentials or bursts over tens of seconds to minutes
for example during seizure activity (Vilin and Ruben, 2001).
The Na+ current mediated by the fast or transient activation and inactivation de-
scribed above is termed transient sodium current (INaT). A small fraction (around
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1%) of VGSCs however can stay open without inactivating or can reopen at later
time points of depolarization resulting in a persistent, non-inactivating Na+ cur-
rent (INaP) that regulates neuronal excitability around and below firing threshold
(Alzheimer et al., 1993; Patlak and Ortiz, 1986). Both of these currents are found in
hippocampal principal cells (Doeser et al., 2014a; Uebachs et al., 2010). A third type
of Na+ current mediated by VGSCs – however not present in hippocampal principal
neurons – is the so-called resurgent current that occurs upon repolarization (Grieco
et al., 2005; Raman and Bean, 1997). Both, differences in the properties of INaT
and INaP were reported in epileptic conditions (Ellerkmann et al., 2003; Mantegazza
et al., 2010).
Sodium channels harbor a wide variety of binding sites for toxins and other
drugs (Catterall, 2017; Stevens et al., 2011; Waszkielewicz et al., 2013). Despite
differences in their precise mode of action, most sodium channel blocking AEDs were
found to bind to the same binding site (neurotoxin binding site 2) in studies replacing
batrachotoxin (BTX) or other toxins from this site (Kuo, 1998; Waszkielewicz et al.,
2013). In addition, the common AED binding site seems to partially overlap with
the local anaesthetic binding site (Tikhonov and Zhorov, 2017; Yang et al., 2010).
Interestingly, binding of BTX (and other site 2 neurotoxins) confers completely
opposite effects on VGSCs than sodium channel blocking AEDs do although binding
to the same primary binding site (Huang et al., 1982; Rogawski et al., 2016; Stevens
et al., 2011; Tikhonov and Zhorov, 2005, 2017). Neurotoxin binding site 2 is located
in the central cavity of the aequous pore and the S6 segments of all four domains
as well as parts of the pore-forming loops seem to contribute to this binding site
(Tsang et al., 2005; Wang and Wang, 2003). In addition to this high affinity binding
site different drugs seem to have multiple low affinity binding sites on VGSCs that
bind drugs more weakly while accessing their primary binding site in the lumen
of the channel pore (Boiteux et al., 2014b; Martin and Corry, 2014; Yang et al.,
2010). Many sodium channel blocking drugs act in a voltage-dependent and activity-
dependent manner which is explained by preferential binding to VGSCs in their
inactivated states (Catterall and Swanson, 2015). After the conformational changes
leading to opening of the channel pore drugs are believed to access and bind their
receptor site in the central cavity more easily than in the resting state (Hille, 1977;
Lipkind and Fozzard, 2010).
Due to differences in structure and mechanism of action, i.e. interaction with
different amino acid residues and functional parts of VGSCs, AEDs can show dif-
ferential effects on multiple properties of VGSCs (Eijkelkamp et al., 2012). Since
INaT and INaP can be mediated by the same channel, it is not surprising that
AEDs can affect both types of currents (Alzheimer et al., 1993; Eijkelkamp et al.,
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2012). Effects on INaP typically involve reductions of the maximal conductance
and can be accompanied by small hyperpolarizing shifts of the voltage dependence
of activation (Doeser et al., 2014b; Stafstrom, 2007; Taverna et al., 1998; Uebachs
et al., 2012, 2010). INaP under normal conditions and especially increased INaP in
epileptic conditions contribute to subthreshold excitability and thus can facilitate
repetitive firing, however, a reduction of the INaP amplitude by AEDs may coun-
terbalance this increased neuronal excitability (Mantegazza et al., 2010; Stafstrom,
2007). On INaT, however, AEDs can exert a broader spectrum of effects including
effects on fast and slow inactivated channels. The effects on fast inactivation include
a slowing of the recovery from VGSC inactivation, as well as shifts in the activation
and inactivation properties (Remy et al., 2003a,b; Vreugdenhil and Wadman, 1999).
Activity-dependent reduction of repetitive action potential firing and slowing of the
recovery from fast inactivation as an underlying mechanism were proposed as a ma-
jor mechanism of action of older AEDs (Kuo et al., 1997). Hyperpolarizing shifts
of the voltage dependence of the steady-state inactivation as well as depolarizing
shifts in the voltage dependence of activation result in reduced channel availabil-
ity and consequently current amplitudes. Notably, those drug-induced shifts occur
exactly in the opposite direction to those shifts that have been described following
epileptogenesis (Ellerkmann et al., 2003; Ketelaars et al., 2001; Vreugdenhil et al.,
1998). Newer anticonvulsants interact with VGSCs in their slow inactivated state
without or with minor effects on fast inactivation processes (Doeser et al., 2014a;
Errington et al., 2008; Hebeisen et al., 2015). These effects include enhancement of
entry into slow inactivated states characterized by hyperpolarizing shifts of the volt-
age dependence of slow inactivation, however, without affecting the recovery time
course. Interactions with slow inactivated channels were proposed to be beneficial
since they would result in stronger reductions of repetitive firing during prolonged
depolarizations e.g. during seizures and much less prominent effects during normal
neuronal activity (Beyreuther et al., 2007).
1.5.2 Carbamazepine
Being in use since the 1960s for treatment of epilepsy and other diseases, carba-
mazepine (CBZ) is among the oldest and most commonly used AEDs (Androsova
et al., 2017; Morselli and Frigerio, 1975). CBZ affects a variety of targets includ-
ing multiple neurotransmitter receptors and ion channels, however the most promi-
nent of its antiepileptic effects are mediated via VGSCs (Ragsdale and Avoli, 1998;
Soares-da-Silva et al., 2015). CBZ binds these channels preferentially in the fast
inactivated state and mediates its antiepileptic effects in a voltage-dependent and
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Figure 2: Schematic diagram of a VGSC complex. Structure of a pseudo-
tetrameric pore-forming α subunit (green/blue) and two modulatory β subunits
(cyan). Each homologous domain of the α subunit is composed of a VSD (green)
and a PD (blue). The membrane reentrant pore-forming loops of each PD harbor
two amino acid residues determining the ion selectivity of the channel (indicated
in yellow). The portion of the intracellular blocking particle important for fast
inactivation by binding to its receptor-sites at the inner mouth of the channel pore
is highlighted in orange. Pore facing residues located in all four S6 segments are
part of neurotoxin bindig site 2 (shown in purple) parts of which are also involved in
high affinity binding of AEDs and other drugs. Redrawn after Stevens et al., 2011,
Catterall and Swanson, 2015, and Das et al., 2016.
activity-dependent (use-dependent) manner by shifting the steady-state inactiva-
tion curve to hyperpolarized potentials, thereby reducing maximal INaT amplitudes
but also by slowing the recovery of fast inactivation (Kuo et al., 1997; Lipkind and
Fozzard, 2010; Ragsdale and Avoli, 1998).
Although being commonly used, a number of drawbacks were reported for CBZ
including induction of its own metabolism and interference with many other drugs
(including AEDs) as well as neurotoxicity due to its active metabolite CBZ epoxide
(Gillham et al., 1988; Morselli and Frigerio, 1975). Potential proepileptic tendencies
of CBZ were also reported (Booker et al., 2015; So et al., 1994). The main problem,
especially in the context of this work, however, is the prominent role of CBZ (but also
other older AEDs) in pharmacoresistance to AEDs (Remy et al., 2003a,b; Schaub
et al., 2007). Studies conducted in different animal models of epilepsy but also
in chronic epileptic tissue of epilepsy patients found a marked reduction or even a
loss of CBZ efficacy (Jandova´ et al., 2006; Lo¨scher and Rundfeldt, 1991; Reckziegel
et al., 1999; Remy et al., 2003a; Uebachs et al., 2010; Vreugdenhil and Wadman,
1999). According to the target hypothesis of pharmacoresistance, changes in the
properties of VGSCs as a target for AEDs may result in reduced efficacy of slowing
the recovery of fast inactivation which translates into reduced blockade of repetitive
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action potential firing and increased seizure activity (Ellerkmann et al., 2003; Remy
and Beck, 2006; see chapter 1.4.1).
1.6 Aim and outline of this thesis
Pharmacoresistance to AEDs is a problem affecting around one third of epilepsy pa-
tients. Loss of efficacy of use-dependent blocking of the older AED carbamazepine
(CBZ) but also reduced blocking effects of other older AEDs were repeatedly re-
ported in tissue resected from chronic epilepsy patients but also in multiple animal
models of epilepsy and consequently and led to the establishment of the target hy-
pothesis of pharmacoresistance.
This thesis addresses the question whether the same or similar phenomena that
result in a reduced efficacy of older anticonvulsants also apply to recently approved
AEDs. Two novel compounds, namely eslicarbazepine (S-Lic) and lacosamide (LCM)
were investigated with respect of their detailed mechanism of action on dentate
gyrus granule cells (DGCs). Previous studies investigated the mechanism of action
of both compounds in cultured neuroblastoma cells and only one other study re-
searched whether fast inactivation processes and repetitive action potential firing
in epileptic versus control tissue are differently affected by S-Lic. Publication one
continues investigating the mechanisms of action of S-Lic in DGCs using the same
approach that was used to reveal loss of efficacy of CBZ, however on the yet fairly
uncharted mechanism of slow inactivation processes under epileptic conditions:
1. Holtkamp, D., Opitz, T., Hebeisen, S., Soares-da-Silva, P., and Beck, H.
(2018). Effects of eslicarbazepine on slow inactivation processes of sodium
channels in dentate gyrus granule cells. Epilepsia 59, 1492–1506.
Publication two adresses the effects of LCM on fast and slow inactivation pro-
cesses as well as action potential firing, again in brain tissue obtained from nonepileptc
and epileptic rats as well as chronic epilepsy patients:
2. Holtkamp, D., Opitz, T., Niespodziany, I., Wolff, C., and Beck, H. (2017).
Activity of the anticonvulsant lacosamide in experimental and human epilepsy
via selective effects on slow Na+ channel inactivation. Epilepsia 58, 27–41.
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2 Effects of eslicarbazepine on slow inactivation
processes of sodium channels in dentate gyrus
granule cells
2.1 Introduction
Novel AEDs are developed with the aim of increasing tolerability or anticonvulsant
potency over existing drugs (Benes et al., 1999; Hainzl et al., 2001). Carbamazepine
(CBZ; first generation) as well as its derivatives oxcarbazepine (OXC; second gen-
eration) and eslicarbazepine acetate (ESL; third generation) represent structurally
related members of the dibenzazepine family of AEDs. Both, OXC and ESL act as
prodrugs for their pharmacologically active metabolites – the R- and S-enantiomers
of licarbazepine (R-Lic, S-Lic). Due to a higher brain penetration, longer half-life
and slightly increased anticonvulsant potency, S-Lic was considered favorable over
R-Lic (Alves et al., 2008; Fortuna et al., 2013; McLean et al., 1994). While around
80% of OXC undergoes stereoselective biotransformation to S-Lic, ESL is almost
completely (∼95%) converted to S-Lic (Almeida et al., 2008; Flesch et al., 1992;
Perucca et al., 2011). In patients treated with ESL, therapeutic mean plasma lev-
els between 10 and 90 µM were reported for S-Lic (Elger et al., 2009; Perucca et
al., 2011). Plasma to whole brain ratios ranging from ∼0.2 to 0.7 were calculated,
however, the actual S-Lic concentration in brain tissue was predicted to be consid-
erably higher since its preference to accumulate in the organic phase of the brain
(Soares-da-Silva et al., 2015).
Although ESL was initially approved for adjunctive treatment and more re-
cently as monotherapy for the treatment of focal seizures, its precise mechanism of
action was not fully determined at the time of approval (Shirley and Dhillon, 2016).
Compared to its precursor-drugs, the metabolites of ESL show strongly reduced
interactions with other AEDs and drug-metabolizing enzymes and seem to cause
less neurological impairment (Arau´jo et al., 2004; Benes et al., 1999; Falca˜o et al.,
2012; Landmark et al., 2016; Morte et al., 2013). Instead, antiepileptogenic potency
was reported (Doeser et al., 2014a). S-Lic acts on a less broad target spectrum
than CBZ including blockade of T-type calcium channels along with its most promi-
nent effects on VGSCs (Soares-da-Silva et al., 2015). While conflicting data on the
modulation of VGSC fast inactivation by S-Lic are available, strong reductions of
repetitive action potential firing were observed in epileptic as well as control tissue
in unaltered magnitude (Doeser et al., 2014a; Hebeisen et al., 2015). Only recently,
potent efficacy in modulation of slow inactivation processes was reported for S-Lic
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in cultured N1E-115 mouse neuroblastoma cells (Hebeisen et al., 2015).
The following publication investigates the so far undetermined effects of S-Lic on
slow sodium channel inactivation processes in rat and human epileptic principal neu-
rons of the DG and sensorimotor cortex and compares those findings to nonepileptic
control cells.
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Summary
Objective: Pharmacoresistance is a problem affecting ∼30% of chronic epilepsy
patients. An understanding of the mechanisms of pharmacoresistance requires a
precise understanding of how antiepileptic drugs interact with their targets in con-
trol and epileptic tissue. Although the effects of (S)‐licarbazepine (S‐Lic) on
sodium channel fast inactivation are well understood and have revealed main-
tained activity in epileptic tissue, it is not known how slow inactivation processes
are affected by S‐Lic in epilepsy.
Methods: We have used voltage clamp recordings in isolated dentate granule
cells (DGCs) and cortical pyramidal neurons of control versus chronically epilep-
tic rats (pilocarpine model of epilepsy) and in DGCs isolated from hippocampal
specimens from temporal lobe epilepsy patients to examine S‐Lic effects on
sodium channel slow inactivation.
Results: S‐Lic effects on entry into and recovery from slow inactivation were
negligible, even at high concentrations of S‐Lic (300 μmol/L). Much more pro-
nounced S‐Lic effects were observed on the voltage dependence of slow inactiva-
tion, with significant effects at 100 μmol/L S‐Lic in DGCs from control and
epileptic rats or temporal lobe epilepsy patients. For none of these effects of S‐Lic
could we observe significant differences either between sham‐control and epileptic
rats, or between human DGCs and the two animal groups. S‐Lic was similarly
effective in cortical pyramidal neurons from sham‐control and epileptic rats.
Finally, we show in expression systems that S‐Lic effects on slow inactivation
voltage dependence are only observed in Nav1.2 and Nav1.6 subunits, but not in
Nav1.1 and Nav1.3 subunits.
Significance: From these data, we conclude that a major mechanism of action of
S‐Lic is an effect on slow inactivation, primarily through effects on slow inactiva-
tion voltage dependence of Nav1.2 and Nav1.6 channels. Second, we demonstrate
that this main effect of S‐Lic is maintained in both experimental and human epi-
lepsy and applies to principal neurons of different brain areas.
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1 | INTRODUCTION
In chronic epilepsy, there is an urgent need for novel
antiepileptic drugs (AEDs). Currently, seizures in ∼30% of
epilepsy patients are insufficiently controlled by drug ther-
apy; this number can be much higher in subtypes of focal
epilepsy. An understanding of the mechanisms of pharma-
coresistance is therefore mandatory and requires a precise
understanding of how AEDs interact with their targets in
control and epileptic tissue.
We had previously shown that transient Na+ channels
in chronically epileptic tissue exhibit a key change that ren-
ders them less susceptible to the anticonvulsant drug carba-
mazepine (CBZ); use‐dependent block of transient Na+
channels is lost in both human and experimental epilepsy,
suggesting that this is a key mechanism underlying phar-
macoresistance to CBZ on the cellular level.1,2 We have
shown that eslicarbazepine (also [S]‐licarbazepine [S‐Lic])
overcomes this potential cellular resistance mechanism to
conventional AEDs.3 S‐Lic is the active metabolite of esli-
carbazepine acetate, a third‐generation member of the
dibenzazepine family of AEDs. After oral administration,
eslicarbazepine acetate is hydrolyzed to S‐Lic, which con-
stitutes its major active metabolite.4
These studies, however, have examined only fast acti-
vation, inactivation, and recovery from inactivation. These
processes take place on a millisecond time scale, as is
appropriate for mediating rapid events such as action
potentials. However, sodium channels invariably show
slow inactivation processes that can modulate the avail-
ability of Na+ channels on a time scale of seconds to
minutes. Slow inactivation processes can powerfully mod-
ulate the availability of Na+ channels in a membrane
potential–dependent manner. In particular, slow inactiva-
tion and recovery will be invoked strongly during pro-
longed depolarization shifts or high‐frequency activity.
Thus, agents that modulate slow inactivation might
potently interfere with ictogenesis under conditions of
increased excitability.
We have therefore systematically investigated effects of
S‐Lic on slow inactivation of sodium channels. We have
examined sodium channels in isolated dentate granule cells
(DGCs) and sensorimotor cortex pyramidal neurons of con-
trol versus chronically epileptic rats (pilocarpine model of
epilepsy) as well as in DGCs isolated from surgical speci-
mens obtained during epilepsy surgery.
2 | MATERIALS AND METHODS
2.1 | Pilocarpine animal model of epilepsy
Epileptic rats were generated as described previously.3,5
Briefly, male Wistar rats (∼200 g) obtained from Charles
River (Wilmington, MA, USA) were housed under a 12‐
hour light/dark cycle and received food and water ad libi-
tum. Status epilepticus (SE) was induced by single
intraperitoneal injections of the muscarinic agonist pilo-
carpine (340 mg/kg; Sigma, Saint Louis, MO, USA)
30 minutes after the administration of methyl‐scopolamine
via the same route (1 mg/kg, Sigma), which aimed at
reducing peripheral muscarinic effects. Around 50% (range
= 20%‐80%) of rats developed and survived SE. SE was
attenuated and eventually terminated by a subcutaneous
injection of diazepam (20 mg/kg; Ratiopharm, Ulm, Ger-
many). Sedated animals were allowed to recover in indi-
vidual cages and were video monitored for the
development of chronic seizures starting approximately
2 weeks after SE. More than 75% (range = 50%‐100%)
of rats experienced video‐documented and therefore
behaviorally detectable seizures and were used as epileptic
animals during this study. Animals that did not develop
seizures following SE were not used in this study. Sham‐
injected control animals were treated equally but were
injected with saline instead of pilocarpine. All experimen-
tal procedures were conducted in accordance with the
guidelines of appropriate animal care committees.
2.2 | Surgical specimens from temporal lobe
epilepsy patients
Hippocampal tissue was obtained from 11 pharmacoresis-
tant epilepsy patients (average age = 42.09 ± 3.37 years)
who underwent surgery to achieve improved seizure control
(for details, see Table S1). Hippocampus sclerosis was
reported in nine of 11 patients. Three of these patients
Key Points
• S-Lic potently reduces sodium current amplitudes
• S-Lic strongly affects slow inactivation at clini-
cally relevant concentrations
• The main effect of S-Lic on slow inactivation is
via a hyperpolarizing shift of the voltage depen-
dence of slow inactivation
• S-Lic activity on voltage dependence of slow
inactivation is maintained in experimental and
human epilepsy
• S-Lic efficacy extends to cortical principal neu-
rons
• Effects are mediated by Nav1.2 and Nav1.6 chan-
nels, whereas Nav1.1 and Nav1.3 are not affected
• S-Lic has multiple modes of action, including
fast inactivation and slow inactivation as well as
antiepileptogenic activity
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suffered from additional pathologic features (ganglioglioma
and malformations of cortical development), and in the last
two patients less pronounced pathological correlates were
apparent. Informed consent was obtained for use of the
specimens. Studies on human tissue were approved by the
institutional research ethics committee.
2.3 | Animal preparation—hippocampal
slices
Experiments were performed 54.9 ± 2.4 days (control
group) to 61.6 ± 6.9 days post‐SE (pilocarpine group).
Animals were anesthetized with ketamine (100 mg/kg) and
xylazine (15 mg/kg) and subsequently perfused through the
heart with ice‐cold, carbogenated (95% O2, 5% CO2; Linde,
Munich, Germany) sucrose‐based artificial cerebrospinal
fluid (ACSF) comprising (in mmol/L) NaCl 60, sucrose
100, NaHCO3 26, KCl 2.5, NaH2PO4 1.25, MgCl2 5,
CaCl2 1, and glucose 20, pH = 7.4, osmolality =
305 mOsm. The brain was rapidly removed and prepared
for slicing.
2.4 | Preparation of rat and human
hippocampal slices and dissociated dentate
granule neurons
Horizontal hippocampal slices (rat, 300 μm; human,
400 μm) were prepared with a vibrating microslicer
(VT1200S; Leica, Wetzlar, Germany) in carbogenated
sucrose ACSF. Rat brains were sectioned in the same
sucrose‐based ACSF as was used during perfusion and sub-
sequently transferred to a storage chamber filled with
sucrose‐based ACSF, prewarmed to 35°C in a water bath,
where they remained for ∼20 minutes. The corresponding
solution used for slicing of human tissue contained (in
mmol/L) NaCl 87, sucrose 75, NaHCO3 25, KCl 2.5,
NaH2PO4 1.25, MgCl2 7, CaCl2 0.5, and glucose 25.
Immediately after their preparation, human hippocampal
slices were stored in ACSF composed of (in mmol/L) NaCl
124, KCl 3, MgCl2 2, CaCl2 2, NaHCO3 26, NaH2PO4
1.25, and glucose 10. Finally, rat as well as human slices
were transferred into a chamber filled with carbogenated
ACSF containing the following (in mmol/L): NaCl 125,
KCl 3.5, MgCl2 2, CaCl2 2, NaHCO3 26, NaH2PO4 1.25,
and glucose 15, pH = 7.4, osmolality = 307 mOsm. Slices
remained there at room temperature until they were used
for preparation of dissociated cells, for a minimal equilibra-
tion period of 30 minutes, however.
Acutely isolated DGCs were obtained by first digesting
one slice at a time for 12 minutes in trituration solution
composed of (in mmol/L) Na methanesulfonate 145, KCl
3, CaCl2 0.5, MgCl2 1, 4‐(2‐hydroxyethyl)‐1‐piperazi-
neethanesulfonic acid (HEPES) 10, glucose 15, pH = 7.4
adjusted with NaOH, osmolality = 315 mOsm, which also
contained pronase (protease type XIV, 2 mg/mL, Sigma),
saturated with oxygen (Linde) and warmed to 36°C. This
step was followed by an equilibration period of 10 minutes
at room temperature (21‐24°C) and a washing step in
enzyme‐free trituration solution. The dentate gyrus was dis-
sected, and the neurons were isolated with fire‐polished
Pasteur pipettes of decreasing aperture in a Nunc dish
(3.5 cm; Thermo Scientific, Waltham, MA, USA). Cells
were allowed to settle for 10 minutes before patch clamp
experiments commenced.
2.5 | Animal preparation—sensorimotor
cortex
Animals were sacrificed 34.2 ± 2.4 days (pilocarpine
group) to 39.9 ± 4.4 days post‐SE (control group). Follow-
ing ketamine/xylazine anesthesia, rats were perfused
through the heart with ice‐cold and carbogenated ACSF
comprising (in mmol/L) NaCl 130, NaHCO3 26, KCl 3,
NaH2PO4 1.25, MgCl2 2, CaCl2 2, and glucose 10, pH =
7.4. The frontal portion of the brain was rapidly removed
and prepared for slicing.
2.6 | Preparation of sensorimotor cortex
slices and dissociated pyramidal neurons
On a vibrating microslicer, a single 500‐μm‐thick coronal
slice comprising primary sensory and motor cortices was
cut approximately 1.8 mm anterior to the bregma. Slicing
in the same ice‐cold carbogenated ACSF that was also used
during perfusion was followed by a 1‐hour recovery period
in the same solution warmed to 32°C. Subsequently, half
of a slice was incubated at 28°C for 90 minutes in oxy-
genated bicarbonate‐free ACSF that contained 25 mmol/L
HEPES instead and was freshly supplemented with
0.01 mmol/L cysteine and 19 U/mL papain on every
experimental day. After a washing step in enzyme‐free
solution, 1‐to 2‐mm‐wide gray matter chunks were pre-
pared and either stored in enzyme‐free solution or triturated
in a Ca2+‐free solution that contained 10 mmol/L
ethyleneglycol‐bis(2‐aminoethylether)‐N,N,N′,N′‐tetraacetic
acid instead, as well as 2 mmol/L freshly added kynurenic
acid as described previously.6
2.7 | Whole cell voltage clamp experiments of
isolated neurons
The trituration solution was exchanged slowly, and cell
debris was washed away with recording solution containing
(in mmol/L) Na methanesulfonate 40, tetraethylammonium‐
Cl 90, CaCl2 1.6, MgCl2 2, HEPES 10, CdCl2 0.2, 4‐ami-
nopyridine 5, glucose 15, pH = 7.4 adjusted with HCl;
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FIGURE 1 Reduction in maximal transient Na+ current (INaT) at resting membrane potential. A, INaT was elicited in rat or human dentate
granule cells by short test pulses (15‐millisecond duration, every 5 seconds) from −90 mV to −10 mV during washin or washout of either 30,
100, or 300 μmol/L (S)‐licarbazepine (S‐Lic). B, Current traces are representative traces of currents with S‐Lic (blue lines) and those recorded in
drug‐free solution (black lines, average of control and washout condition). C, On average, INaT was reduced by 7.09 ± 3.26%, 3.40 ± 1.32%, and
2.27 ± 2.75% in response to 30 μmol/L S‐Lic, further reduced by 19.72 ± 1.75%, 22.44 ± 2.22%, and 19.87 ± 7.97% following perfusion of
100 μmol/L S‐Lic, and even further reduced by 24.05 ± 2.79%, 23.71 ± 2.49%, and 25.37 ± 3.75% in the presence of 300 μmol/L S‐Lic, in
granule cells isolated from sham‐injected rats, epileptic rats, and human epilepsy patients, respectively. SE, status epilepticus
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osmolality = 310 mOsm adjusted with glucose. The record-
ing pipettes were pulled from borosilicate glass capillaries
(0.86 mm inner diameter, 1.5 mm outer diameter, with fila-
ment; Science Products, Hofheim, Germany) using a micro-
pipette puller (Model P‐97; Sutter Instruments, Novato,
CA, USA) and were filled with intracellular solution that
contained (in mmol/L) CsF 110, HEPES‐Na 10, ethyleneg-
lycoltetraacetic acid 11, MgCl2 2, tetraethylammonium‐Cl
20, Na2‐GTP 0.5, ATP‐Na2 5, pH = 7.25 adjusted with
CsOH, osmolality = 300 mOsmol. Patch pipettes displayed
open tip resistances ranging from 4 to 7 MΩ in the bath
solution. With the Nunc dish mounted on an inverted
microscope (Axiovert 100; Zeiss, Gottingen, Germany),
isolated granule cells were identified by their morphology
as described previously.7,8 Putative cortical pyramidal neu-
rons were selected by their roundish‐triangular morphology
independent of soma size, which could vary from slightly
larger to several‐fold the size of DGCs. After formation of
tight seal‐resistances > 1 GΩ, the plasma membranes were
ruptured, and transient Na+ currents (INaTs), were recorded
at room temperature under constant superfusion with oxy-
genated recording solution using a patch clamp amplifier
(Axopatch 200B; Molecular Devices, Sunnyvale, CA,
USA). Currents were filtered at 10 kHz, sampled at
50 kHz using a Digidata 1440A, and stored on a personal
computer running Clampex 10.2 (Molecular Devices). Ser-
ies resistance of recorded rat pyramidal neurons, and rat
and human granule cells was 7.18 ± 0.53 MΩ,
7.95 ± 0.21 MΩ, and 6.89 ± 0.38 MΩ, respectively, and
could be compensated between 75% and 85% resulting in
maximal residual voltage errors of 3.41 ± 0.39 mV and
4.48 ± 0.19 mV for rat and 3.94 ± 0.52 mV for human
recordings. Leak current was generally below 300 pA,
input resistance between 300 and 800 MΩ, and series resis-
tance ranged from 5 to 10 MΩ. Cells deviating signifi-
cantly from these values were discarded. Neurons
experiencing jumps in leak current resulting in sudden
alterations of the peak amplitude and neurons with a rapid
rundown of current amplitude resulting in currents too
small for meaningful analyses were also discarded.
Measured as well as command potentials were corrected
for a calculated liquid junction potential of 10.0 mV.
2.8 | Expression systems
Stably transfected cell lines expressing human Nav1.1 αβ1
or Nav1.2 αβ1 sodium channels (both in HEK‐293 cells;
Scottish Biomedical, Glasgow, UK) or stably transfected
cell lines expressing human Nav1.3 α or Nav1.6 α sodium
channels (both in CHO‐K1 cells; B'SYS, Witterswil,
Switzerland) were grown in Dulbecco modified Eagle med-
ium (Sigma‐Aldrich, Saint Louis, MO, USA; containing
2 μg/mL blasticidin and 600 μg/mL geneticin [Nav1.1 and
Nav1.2]) or HAM F12 medium (Sigma‐Aldrich; containing
500 μg/mL geneticin [Nav1.3] or 100 μg/mL hygromycin
[Nav1.6]) supplemented with 0.15 mg/mL L‐glutamine,
10% fetal bovine serum (Sigma‐Aldrich), and 1% peni-
cillin/streptomycin under standard laboratory conditions
(37°C, 5% CO2, 95% relative humidity) and passaged at a
confluence of 50%‐80%.
For electrophysiological recordings 4‐48 hours after the
last passaging, cells were transferred to 35‐mm culture
dishes (Nunc) at a confluence suitable for recording from
single cells. The cell culture medium was exchanged with
recording solution containing (in mmol/L) Na methanesul-
fonate 30, NaCl 34.25, KCl 1, tetraethylammonium‐Cl
67.5, CaCl2 1.65, MgCl2 1.75, CdCl2 0.15, HEPES 10,
4‐aminopyridine 3.75, glucose 13.75, pH = 7.4 adjusted
with HCl. Patch pipettes were pulled from borosilicate
glass capillaries (0.86 mm inner diameter, 1.5 mm outer
diameter, with filament; Warner Instruments, Hamden, CT,
USA) on a vertical micropipette puller (P‐10; Narishige,
Tokyo, Japan) and filled with intracellular solution of iden-
tical composition as used for isolated cells. Open tip resis-
tances ranged between 2 and 7 MΩ, series resistance was
7.52 ± 0.30 MΩ, and resistance was compensated by at
least 50%. Recordings were obtained using an EPC‐9/10
patch clamp amplifier (HEKA, Lambrecht, Germany) and
PatchMaster software (HEKA) under the same conditions
as stated above for isolated neurons.
FIGURE 2 Increased entry into slow inactivation. A, Entry of Na+ channels into slow inactivation was induced by depolarizing dentate
granule cells (DGCs) with a conditioning pulse for 1, 10, or 30 seconds from −90 mV holding potential to −10 mV. To allow recovery from
fast inactivation, cells were repolarized for 1 second, and subsequently the fraction of channels available was determined by a 15‐millisecond test
pulse. The reduction compared to the current amplitude initiated by the conditioning pulse is due to slow inactivation. B, Representative
recordings of Na+ currents elicited by different conditioning pulses (black traces) or the test pulse 1 second after the end of the depolarizations
(red traces). Examples from a granule cell of a sham‐injected rat, a pilocarpine‐treated rat, and an epilepsy patient. C, Lower transient Na+
current amplitudes as seen in B indicate increased slow inactivation of Na+ channels in response to longer conditioning pulse durations. In both
sham‐injected and pilocarpine‐treated rats, blocking effects increased slightly after washin of 300 μmol/L (S)‐licarbazepine (S‐Lic). D, Additional
blocking effects were also seen in human DGCs. E, All three experimental groups do not differ in observed S‐Lic effect sizes at any conditioning
pulse duration. *P < 0.05, **P < 0.01, and ***P < 0.001. ACSF, artificial cerebrospinal fluid; SE, status epilepticus
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2.9 | Drugs
Stock solutions of S‐Lic (obtained from Bial, São Mamede
do Coronado, Portugal) were prepared freshly once per
experimental day in dimethylsulfoxide (Merck, Darmstadt,
Germany; Sigma) and added to the recording solution at
1:1000 (isolated cells). For cultured cells, the stock solution
was diluted in recording solution and the final dimethylsul-
foxide concentration was adjusted to 0.4% in all groups. The
drug‐free recording solution always contained equal amounts
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of dimethylsulfoxide. Throughout the Results and Discus-
sion, the drug‐free recording solution will be abbreviated as
“base & wash” or “ACSF,” although being of different com-
position than ACSF stated above, whereas an identical solu-
tion containing S‐Lic will be termed “S‐Lic” with or without
the respective concentration. In expression systems, only one
test concentration or ACSF was tested per cell.
2.10 | Data analysis—isolated neurons
For the drug‐dependent reduction of the peak INaT amplitude,
currents recorded in drug‐free recording solution (average of
the first current of the washin phase and the last current of
the washout phase of S‐Lic) were compared to currents
recorded in bath solution containing additional S‐Lic (aver-
age of the last current of the drug washin and the current
recorded at the beginning of the washout phase).
The change in INaT amplitudes was analyzed by com-
paring normalized currents elicited (by test pulses) during
inactivation to the initial current amplitude (elicited by the
conditioning pulse or a test pulse preceding the condition-
ing pulse) of each recording. Also, baseline values before
washin of S‐Lic and values after washout of the drug were
averaged and compared to the values of the S‐Lic record-
ings to correct for rundown effects over the duration of the
experiments. Datasets for the voltage dependence of slow
inactivation were additionally normalized to the current
recorded after hyperpolarizing the granule cell, as this was
generally the largest of all recorded currents.
The time course of the recovery of slow inactivation
was fitted to the following biexponential function using a
Levenberg‐Marquardt algorithm:
IðtÞ ¼ A0 þ Aslow1  et=τslow1 þ Aslow2  et=τslow2
with τslow1 and τslow2 being the slow and ultraslow time
constant of recovery, Aslow1 and Aslow2 as their relative
amplitude contributions, and I(t) as the normalized current
amplitude at time point t offset by A0.
2.11 | Data analysis—cultured cells
In cultured cells, only one test concentration was tested per
cell. The ratio of normalized (Inorm) amplitudes obtained
after and before the conditioning pulse was plotted against
the conditioning pulse voltage for each tested concentration
and fitted with a sigmoidal equation:
Inorm ¼ Imin þ ðImax  IminÞ=1þ 10ððV50XÞHÞ
with Imax being the maximal normalized current fixed to 1
and Imin the remaining fraction of not slowly inactivated
channels, X being the command potential, V50 the potential
at half maximal inactivation, and H the Hill coefficient.
2.12 | Statistical analysis
All statistical tests were performed at a significance level α of
0.05. For statistical comparison of τ values, paired t tests were
used. Individual voltage dependence experiments were ana-
lyzed by analysis of variance (ANOVA) with proper posttests
mentioned in each individual experiment. If assumptions for
an ANOVA were not met, appropriate nonparametric tests
were used, which are also indicated for each individual statisti-
cal comparison. Normality was tested using a Shapiro‐Wilk
test. Results and other given values are presented as
mean ± standard error of the mean. For posttest results omitted
in the main text body see Table S3. Fitting and statistics were
made in Prism 7 (GraphPad Software, La Jolla, CA, USA).
3 | RESULTS
3.1 | S‐Lic reduces INaT amplitudes at resting
membrane potential
We first determined the effects of S‐Lic on sodium cur-
rents elicited from (hyperpolarized) potentials close to the
resting membrane potential of DGCs, at which channels
are fully recovered from fast inactivation. INaT was
evoked by depolarizing DGCs from −90 mV to −10 mV
before, during, and after perfusion of different concentra-
tions (30, 100, 300 μmol/L) of S‐Lic (Figure 1A). Con-
centration‐dependent effects of S‐Lic on INaT could be
observed in granule cells isolated from sham‐injected rats,
epileptic rats, and human epilepsy patients (Figure 1B,
black vs blue traces, summary with numbers given in Fig-
ure 1C). These data suggest that S‐Lic exerts strong
effects on sodium channels aside from the known effects
on fast inactivation.
3.2 | S‐Lic effects on entry into and recovery
from slow inactivation
We next tested the idea that the entry into slow inactiva-
tion, or the recovery from slow inactivated states, is
affected by S‐Lic. Entry of Na+ channels into slow inacti-
vation was induced by depolarizing rat and human DGCs
for 1, 10, or 30 seconds from −90 mV holding potential
to −10 mV. A 15‐millisecond test pulse 1 second after
the end of the conditioning pulse was used to determine
the reduction of the INaT amplitude by slow inactivation
processes, as described previously (Figure 2A). In DGCs
of sham‐injected and epileptic rats as well as human
patients, increasing the duration of the conditioning pre-
pulses from 1 to 30 seconds caused a strong reduction in
INaT due to increased entry into slow inactivation (Fig-
ure 2B, red traces vs black traces). In both rat groups, the
fraction of channels entering slow inactivation was
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FIGURE 3 Unaltered recovery from slow inactivation. A, The time course of recovery from Na+ channel slow inactivation was studied by
applying 50 additional test pulses every 3 seconds following the conditioning pulse used to induce slow inactivation. B, Individual currents
recorded in response to the conditioning pulse and test pulses to track recovery from slow inactivation over time for dentate granule cells (DGCs)
isolated from normal rats, epileptic rats, and human epilepsy patients. C, Average recovery time course for both groups of rat granule cells in
drug‐free recording solution and under 300 μmol/L (S)‐licarbazepine (S‐Lic). D, Equivalent experimental results for human DGCs. ACSF,
artificial cerebrospinal fluid; SE, status epilepticus
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enhanced in response to 300 μmol/L S‐Lic (Figure 2C,
two‐way ANOVA, sham control: F1, 18 = 38.69,
P < 0.001; post‐SE: F1, 18 = 52.82, P < 0.001, with
*P < 0.05, **P < 0.01, and ***P < 0.001 in Bonferroni
multiple comparisons test for S‐Lic efficacy). Similar
results were obtained from human epileptic DGCs (Fig-
ure 2D, two‐way ANOVA, human epilepsy: F1,
12 = 25.15, P < 0.001, posttest as for rat groups). These
effects were rather small and did not differ between all
three experimental groups (Figure 2E, Kruskal‐Wallis test
1500 | HOLTKAMP ET AL.
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with Dunn multiple comparisons test, not significant).
Lower concentrations of S‐Lic (100 μmol/L, Figure S1)
similarly increased the entry into slow inactivation (Fig-
ure S1B, C, and D, experiments done as in Figure 2).
Again, the effect sizes were indistinguishable between
both rat groups (Figure S1D, Mann‐Whitney test, not sig-
nificant). Collectively, these data show significant, but
small, effects on entry into slow inactivation, with magni-
tudes below 10% of the maximal current amplitude.
We then studied the time course of recovery from Na+
channel slow inactivation using established protocols.
Briefly, slow inactivation was induced with a prolonged
voltage step of 1, 10, or 30 seconds. Subsequently, the
recovery from inactivation was monitored using brief test
pulses applied every 3 seconds (Figure 3A). This protocol
allows determination of the time course of recovery as a
gradual increase in the INaT measured during the brief test
pulses (Figure 3B, examples depicted for sham‐control rats,
epileptic rats, and human epilepsy patients in the absence
and presence of 300 μmol/L S‐Lic). The average recovery
time course for both groups of rat granule cells and for
human granule cells is depicted in Figure 3C and 3D,
respectively. Similar recordings with 100 μmol/L S‐Lic are
depicted in Figure S2. As already apparent from these
recordings and recovery time courses, the time constants
derived after fitting the recovery of individual granule neu-
rons were also largely unaffected by 100 or 300 μmol/L S‐
Lic (Figure S3, paired t test for comparison of recovery
time constants, Wilcoxon matched‐pairs test for comparison
of fractions of slow and ultraslow recovery). Thus, both
entry and recovery from inactivation are largely unaffected
even by high concentrations of S‐Lic (300 μmol/L).
3.3 | S‐Lic strongly shifts the voltage
dependence of slow inactivation to
hyperpolarized potentials
To determine additional mechanisms that could account for
the reduction in INaT via effects on slow inactivation, we
studied whether S‐Lic affects the voltage dependence of
slow inactivation. To this end, we used a conditioning volt-
age protocol consisting of 10‐second steps to various volt-
ages between −110 mV and −30 mV to induce slow
inactivation. Voltage‐dependent inactivation was then
assessed by determining the fraction of INaT inactivated by
the conditioning pulse (Figure 4A, INaT assessed by brief
test pulses before and after the conditioning pulse). Repre-
sentative recordings are shown in Figure 4B for INaT pre-
ceding a conditioning pulse (black lines) and INaT evoked
after the conditioning pulse (10 seconds, −70 mV, red
lines).
In the presence of 100 μmol/L S‐Lic, significant reduc-
tions in INaT amplitudes were found for all conditioning
pulse voltages in rat as well as human granule cells (Fig-
ure 4C, two‐way ANOVA, sham control: F1, 52 = 189.1,
P < 0.001; pilocarpine‐treated: F1, 48 = 301.2, P < 0.001;
human epilepsy: F1, 24 = 73.24, P < 0.001; followed by
Bonferroni multiple comparisons test for S‐Lic efficacy
with **P < 0.01 and ***P < 0.001). We performed
equivalent experiments applying 30 μmol/L and
300 μmol/L S‐Lic (summarized in Figure 4E). Whereas
30 μmol/L S‐Lic resulted in nonsignificant shifts, the
effects seen for 300 μmol/L S‐Lic were slightly more
prominent than those observed for 100 μmol/L S‐Lic.
(Figure 4D, two‐way ANOVA, sham control: F1,
20 = 162.7, P < 0.001; pilocarpine‐treated: F1,
20 = 71.43, P < 0.001; human epilepsy: F1, 16 = 229.5,
P < 0.001; followed by Bonferroni multiple comparisons
test for S‐Lic efficacy with *P < 0.05, **P < 0.01, and
***P < 0.001). For all tested drug concentrations, the
efficacy of S‐Lic on DGCs was unaltered between
nonepileptic and epileptic rats (Figure 4E, white and black
bars, Mann‐Whitney test, not significant) as well as
between rats and human epilepsy patients (Kruskal‐Wallis
test with Dunn multiple comparisons test, not significant).
These data indicate that strong effects of S‐Lic are
observed on the voltage dependence of slow inactivation
that seem to saturate at concentrations > 100 μmol/L.
FIGURE 4 Potent hyperpolarizing shifts of the voltage dependence of slow inactivation. A, Voltage step protocol used to study the voltage
dependence of Na+ channel slow inactivation. A short test pulse to −10 mV was followed by variable conditioning pulse potentials ranging from
−110 to −30 mV. Another test pulse was applied after recovery from fast inactivation at holding potential (−90 mV) 1 second after the end of
the conditioning pulse. B, Representative examples of recorded Na+ currents elicited by the test pulse before (black lines) and after a 10‐second
conditioning pulse to −70 mV (red lines). Note overall reduced current amplitudes and increased slow inactivation in the presence of 100 μmol/L
(S)‐licarbazepine (S‐Lic). C, D, Summary of individual test pulse amplitudes normalized to the averaged baseline and washout test pulse
amplitude following the −110‐mV conditioning pulse. Averaged baseline and washout amplitudes (white symbols) were compared to those
recorded under S‐Lic (black symbols; C, 100 μmol/L; D, 300 μmol/L), resulting in significant amplitude reductions caused by a prominent
hyperpolarizing shift of the voltage dependence. E, Effects of 30, 100, and 300 μmol/L S‐Lic on the voltage dependence of slow inactivation for
all three experimental groups were compared for each conditioning pulse voltage. None of the tested S‐Lic concentrations resulted in significant
differences at any tested conditioning pulse voltage, irrespective of comparing only healthy and epileptic rats (white vs black bars, Mann‐
Whitney test, not significant) or both rat groups and human epilepsy patients (white, black, and gray bars, Kruskal‐Wallis test with Dunn
multiple comparisons test, not significant). *P < 0.05, **P < 0.01, and ***P < 0.001. SE, status epilepticus
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They also demonstrate that these effects are maintained in
chronic experimental and human epilepsy.
3.4 | S‐Lic shows similar efficacy in epileptic
and healthy cortical pyramidal neurons
We were curious whether the efficacy of S‐Lic in chronic
epileptic tissue is limited to hippocampal neurons or
extends to extrahippocampal brain areas. Therefore, we
studied the effects of S‐Lic on voltage dependence of slow
inactivation in isolated neocortical pyramidal neurons in
nonepileptic and epileptic rats (Figure 5A). Similar to the
results in DGCs, 100 μmol/L S‐Lic reduced the maximal
average INaT amplitude by 16.2 ± 3.9% and 19.7 ± 4.4%
in sham control and pilocarpine‐treated rats, respectively
(examples in Figure 5B, calculated as for DGCs in
FIGURE 5 Similar efficacy in cortical pyramidal neurons. A, Same voltage step protocol as used to study the voltage dependence of Na+
channel slow inactivation in dentate granule cells. B, Example transient Na+ current recordings before (black lines) and after a 10‐second
conditioning pulse to −70 mV (red lines) under averaged predrug and postdrug application and under 100 μmol/L (S)‐licarbazepine (S‐Lic). C,
Averaged current amplitudes from baseline and drug washout conditions (white symbols) and in the presence of 100 μmol/L S‐Lic (black
symbols) normalized to the test pulse recorded 1 second after the nondrug −110‐mV conditioning pulse. Significantly reduced current amplitudes
were revealed by two‐way analysis of variance (sham control: F1, 16 = 73.83, P < 0.001; pilocarpine‐treated: F1, 28 = 74.12, P < 0.001;
Bonferroni multiple comparisons test for S‐Lic efficacy with *P < 0.05, **P < 0.01, and ***P < 0.001). D, No significant differences in effect
sizes between epileptic and nonepileptic pyramidal neurons at any tested voltage
1502 | HOLTKAMP ET AL.
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Figure 1). Voltage‐dependent S‐Lic effects were also
observed in pyramidal neurons, again with the strongest
effects at intermediate voltages close to the resting mem-
brane potential (Figure 5C and 5D). The drug effect sizes
were also indistinguishable between pyramidal neurons
isolated from healthy and epileptic brains (Figure 5D,
Mann‐Whitney test, not significant). From these data, we
conclude that S‐Lic exerts antiepileptic potency in DGCs
as well as cortical pyramidal neurons to a similar extent,
both in epileptic and nonepileptic tissue.
FIGURE 6 Sodium channel isoform‐specific effects of (S)‐licarbazepine. A, Voltage step protocol used to examine voltage dependence of
slow inactivation in expression systems expressing either Nav1.1, Nav1.2, Nav1.3, or Nav1.6 channels. A 20‐millisecond test pulse to −10 mV
was applied 1 second before and 1 second after a 10‐second conditioning pulse ranging from −120 to +40 mV in either 20‐ or 10‐mV
increments. B, Dose‐dependent hyperpolarizing shifts of the voltage‐dependence curves and increases in the fraction of slow inactivated channels
were observed for Nav1.2 and Nav1.6 but not Nav1.1 and Nav1.3 channels. Dashed lines indicate the more confined voltage range tested in
isolated neurons
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3.5 | S‐Lic effects are predominantly
mediated via Nav1.2 and Nav1.6 sodium
channel isoforms
Finally, we investigated the effects of different concentra-
tions of S‐Lic on relevant brain sodium channel isoforms
expressed in either CHO or HEK cells. In these experi-
ments, we were able to assess a more extensive range of
voltage, due to the high stability of recordings in expres-
sion systems (Figure 6A). In cells expressing Nav1.1 or
Nav1.3 channels, no or very limited effects on the voltage
dependence of slow inactivation were observed up to con-
centrations of 1000 μmol/L S‐Lic (Figure 6B, left panels).
In contrast, in cells expressing Nav1.2 or Nav1.6, a strong
hyperpolarizing shift of the voltage‐dependence curves and
an additional increase in the fraction of slow inactivated
channels could be observed in the presence of S‐Lic
(Figure 6B, right panels). These effects were strongly dose‐
dependent and increased with higher concentrations of
S‐Lic. Interestingly and in contrast to all other tested
sodium channel isoforms, obvious yet insignificant S‐Lic
effects on Nav1.2 channels were already apparent at very
low S‐Lic concentrations of 10 μmol/L (Table S2; ANOVA
followed by Dunnett posttest for V50 and Kruskal‐Wallis
test followed by Dunn posttest for Imin).
4 | DISCUSSION
The main result of this study is that S‐Lic exhibits strong
effects of sodium channel slow inactivation, mainly via
effects on the voltage dependence of slow inactivation in
native human and rat neurons. These effects are confined
to Nav1.2 and Nav1.6 subunits and are not observed in
Nav1.1 and Nav1.3 subunits. Moreover, the efficacy of
S‐Lic in modulating slow inactivation voltage dependence
is maintained in chronic human and experimental epilepsy
and extends to principal cells of at least the two
investigated brain areas.
The strong effects on slow inactivation seen for S‐Lic
have been observed previously in expression systems.9
Similar effects are shared by some other AEDs. Lacosa-
mide also exerts effects on slow inactivation in different
types of neurons.5,10,11 Moreover, as seen for S‐Lic, lacosa-
mide also shifts the voltage dependence of slow inactiva-
tion in a hyperpolarizing direction as a major effect,
whereas other effects on slow inactivation were small.5,10
In contrast to those AEDs, the effects of CBZ on slow
inactivation are virtually negligible, with well‐known pro-
nounced effects on fast inactivation processes.9 Lacosamide
does differ from S‐Lic in that effects on fast inactivation
voltage dependence were undetectable or small,5,10,11
whereas S‐Lic does have significant effects on fast sodium
channel gating in native neurons.3 Another study, however,
did not find significant S‐Lic effects on fast inactivation in
expression systems.9 These findings underscore that sodium
channel blockers are not by any means equivalent. Rather,
they show marked differences in how they act on different
kinetic parameters of sodium channels, in this case in par-
ticular slow versus fast inactivation. The structural basis for
these differences is unclear, but the question of why these
compounds behave differently is intriguing. Molecular
modeling approaches may be extremely useful to determine
candidate mechanisms related to the interaction between
AEDs and channel structures.12
A further difference between AEDs is additional targets
aside from voltage‐gated Na+ channels. Sodium channels
are not the only targets for S‐Lic, with T‐type calcium
channels being another relevant target that may be respon-
sible for antiepileptogenic mechanisms of action.3 In con-
trast, sodium channels seem to be the major target for
lacosamide, as binding studies have excluded binding of
lacosamide to different types of γ‐aminobutyric acid and
glutamate receptors, as well as a variety of other neuro-
transmitter receptors, and voltage‐gated potassium or cal-
cium channels.13,14
A first question addressed in this study was whether the
effects of S‐Lic are maintained in chronic epilepsy. A pre-
vious study has shown that the active metabolite of the
anticonvulsant eslicarbazepine acetate has potent use‐
dependent effects in experimental and human epilepsy,
and has add‐on effects to CBZ.3 Is this also the case for
slow inactivation? Our data show that the answer to this
question is yes. We observed quantitatively maintained
effects of S‐Lic not only on slow inactivation in experi-
mental epilepsy, but also on sodium channels in granule
cells obtained from epilepsy surgical specimens. This is
similar to the maintained activity of lacosamide on slow
inactivation and use‐dependent block in chronic experi-
mental and human epilepsy that was observed in a previ-
ous study.5 In addition, we have shown that the
maintained activity also extends to cortical areas, which
also display pathological changes in chronic epilepsy
models.15-17
Given the prominent effects of S‐Lic on the voltage
dependence of slow inactivation in different types of native
neurons, we examined which Na channel alpha subunits
are responsible for this effect. The results were surprisingly
clear—Nav1.1 and Nav1.3 slow inactivation is not affected
by S‐Lic even at high concentrations, whereas strong
effects are seen for Nav1.2 and Nav1.6. The largest effects
of S‐Lic could be observed on Nav1.2 channels with potent
effects even at low concentrations of 10 μmol/L.
Nav1.2 and Nav1.6 channels are both expressed promi-
nently in principal neurons. In contrast, Nav1.1 is strongly
expressed in fast‐spiking interneurons.18 This may argue
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for a cell type–specific inhibitory action of S‐Lic that
spares interneurons enriched in Nav1.1. Moreover, this
specificity positions S‐Lic as a potential anticonvulsant
therapy in diseases with compromised Nav1.1 function in
interneurons, such as loss‐of‐function Nav1.1 mutations or
Alzheimer’s disease.19-22 Intriguingly, in Alzheimer’s dis-
ease, anticonvulsants that block Na+ channels indiscrimi-
nately are ineffective, presumably because they further
impair interneuron functionality, whereas levetiracetam,
which has a presynaptic mode of action, is effective.23 This
and these previous studies suggest that AED effects on
slow inactivation are an important mode of action that is
surprisingly isoform specific.
Two important considerations emerge from these and
published data. First, it may be important to develop AEDs
with multiple modes of action such as S‐Lic; however, far
from being indiscriminate, each of these modes of action
shows a sometimes surprising specificity for ion channel
isoforms. It has been argued with a similar logic that classi-
cal use‐dependent Na+ channel blockers could be meaning-
fully combined with other compounds with different
specificity. Future studies will have to show whether com-
bining specific modes of action shows synergistic effects,
both in animal models and in humans. Second, it will be
increasingly important to show that anticonvulsant mecha-
nisms of action are maintained in chronic epilepsy, as
shown for S‐Lic with respect to effects on both fast and
slow inactivation. Developing such compounds with multi-
ple specific mechanisms of action that are stable even in
chronic epilepsy will be important to overcome target
mechanisms of pharmacoresistance.
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Supplementary Fig. 1: Lower concentrations of S-Lic also increase entry into slow 
inactivation. (A) Washing in recording solution that contained 100 µM instead of 300 µM S-
Lic, the same voltage step protocol as explained in Fig. 2 was used. (B) Representative 
recordings of Na+ currents following 1, 10 and 30 second depolarizing conditioning pulses in 
normal rats and epileptic rats (color scheme as in Fig. 2). (C) Following S-Lic application, 
lower Na+ currents were recorded in DGCs of both rat groups (two-way ANOVA, sham 
control: F(1, 18)=28.4, p<0.001; post-SE: F(1, 18)=19.91, p<0.001, with * indicating p<0.05, ** 
p<0.01 and *** p<0.001 in Bonferroni's multiple comparisons test for S-Lic efficacy. (D) 
Effect sizes do not differ between both rat groups (Mann-Whitney test, n.s.). 
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Supplementary Fig. 2: Unaltered recovery from slow inactivation following 100 µM S-Lic. 
(A) Experiments as described in Fig. 3 were replicated in presence of 100 µM instead of 300 
µM S-Lic using identical protocols. (B) Individual currents recorded at the beginning of and 
after the conditioning pulse for dentate granule cells isolated from normal and epileptic rats. 
(C) Averaged time course of recovery from slow inactivation for both groups of rat granule 
cells in drug-free recording solution and following perfusion of 100 µM S-Lic. 
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Supplementary Fig. 3: Similar recovery time constants and fractions of slow and ultra slow 
recovery. Summary of recovery parameters derived after fitting the recovery of individual 
DGCs (see methods for details). The slow and ultra-slow time constants of recovery as well as 
the fraction of channels recovering with given time constants are summarized in (A) for 
ACSF vs 100 µM S-Lic and in (B) for ACSF vs 300 µM S-Lic. Paired t-test for comparison 
of recovery time constants and Wilcoxon matched-pairs test for comparison of fractions of 
slow and ultra slow recovery. 
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Patient 
ID 
 
Age at 
surgery 
 
Gender 
 
No 
cells 
 
Type of 
recording 
 
Part of Fig. 
 
Type of surgery 
 
Pathology 
Treated 
with ESL / 
OXC * 
 
Current 
medication 
 
Past medication 
 
P1 
 
44 
 
m 
 
3 
 
VC 
 
1, 4, 5 
temp. pole resection & 
AH right 
 
AHS right 
 
no 
 
OXC, LEV 
 
GBP, PGB 
 
P2 
 
53 
 
f 
 
2 
 
VC 
 
1, 4, 5 
temp. pole resection & 
AH left 
temp. pole loss of grey-white 
matter differentiation & AHS l 
 
no 
 
CLB, PER, PB 
 
same 
 
P3 
 
54 
 
f 
 
2 
 
VC 
 
1, 4, 5 
 
sel. AH right 
 
AHS right 
 
no 
 
LEV, LTG 
CBZ, PB/PRM, 
GBP, LCM 
P4 39 f 1 VC 1-3, S3 sel. AH left AHS left no ZNS LEV 
 
P5 
 
14 
 
m 
 
1 
 
VC 
 
1, 4, 5 
sel. AH & temp. pole 
resection right 
temp. pole loss of grey-white 
matter differentiation & AHS r 
 
no 
 
VPA, LEV, CLB 
 
same 
 
P6 
 
54 
 
m 
 
2 
 
VC 
 
1-5, S3 
temp. pole resection & 
AH left 
 
Ganglioglioma & AHS left 
 
no 
 
LEV, LTG 
 
VPA 
P7 18 m 2 VC 1, 5 sel. AH right AHS right yes LTG, LEV OXC, VPA, ST 
 
P8 
 
37 
 
m 
 
1 
 
VC 
 
1, 5 
 
sel. AH right 
 
AHS right 
 
no 
PB/PRM, LEV, 
ZNS 
 
same 
 
P9 
 
41 
 
m 
 
1 
 
VC 
 
1, 4, 5 
temp. pole resection & 
AH left 
 
Reactive astrogliosis 
 
no 
CBZ, VPA, 
TPM 
PB/PRM, LTG, 
LEV 
 
P10 
 
59 
 
f 
 
2 
 
VC 
 
1, 4, 5 
 
sel. AH right 
Volume accentuation of right 
amygdala, likely past limbic 
encephalitis 
 
no 
 
LEV 
 
VPA, LTG, LCM 
 
P11 
 
50 
 
f 
 
4 
 
VC 
 
1-3, 5, S3 
 
sel. AH left 
 
AHS left 
 
no 
 
LCM, LTG, LEV 
CBZ, LCM, LTG, 
TPM 
 
Supplementary Table 1: Overview of patients with refractory TLE included in the study. Sel. AH, selective amygdalohippocampectomy; AHS, 
Ammon’s horn sclerosis; ESL, eslicarbazepine acetate; OXC, oxcarbazepine; LEV, levetiracetam; GBP, gabapentin; PGB, pregabalin; CLB, clobazam; PER, 
perampanel; PB, phenobarbital; PRM, primidone;  LTG, lamotrigine; CBZ, carbamazepine; LCM, lacosamide; ZNS, zonisamide; VPA, valproic acid; ST, 
sultiam; TPM, topiramate; * ESL and OXC share S-Lic as their major active metabolite; see patient data. 
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V50 (mV) S-Lic concentration Statistics (Dunnett's post-test) 
 
0 µM 10 µM 100 µM 1000 µM 0 vs 10 0 vs 100 0 vs 1000 
Nav1.1 -47.5±1.9 -48.6±2.5 -44.7±0.9 -49.4±1.8 0.959  0.559  0.803 
Nav1.2 -42.2±1.4 -47.6±1.3 -51.8±2.7 -62.9±1.6 0.108 0.002     ** <0.001 *** 
Nav1.3 -34.4±1.9  -39.6±1.3 -37.0±2.0 -40.5±2.0 0.155  0.650  0.071 
Nav1.6 -39.2±1.6  -43.4±2.4 -45.3±1.9 -52.5±1.3 0.253 0.065 <0.001 *** 
 
Imin (%) S-Lic concentration Statistics (Dunn's post-test) 
 
0 µM 10 µM 100 µM 1000 µM 0 vs 10 0 vs 100 0 vs 1000 
Nav1.1 71.4±1.8 72.6±2.7 68.1±2.8 67.7±2.5 >0.999  >0.999  0.702 
Nav1.2 72.8±1.6 52.0±2.4 34.9±2.9 22.0±2.2 0.155 <0.001 *** <0.001 *** 
Nav1.3 67.7±1.6 66.5±1.7 67.0±1.8 62.6±2.9 >0.999  >0.999  0.348 
Nav1.6 59.3±3.1 56.4±2.4 38.1±1.6 27.8±3.3 >0.999 0.004     ** <0.001 *** 
 
Supplementary Table 2: Detailed data for the potential of half maximal inactivation (V50) and 
the remainder fraction of sodium channels not being in slow inactivated state (Imin) both 
derived from fitting with a sigmoidal equation (n = 9-10 per condition). Potential 
hyperpolarizing shifts of V50 or decreases in the fraction of available channels between drug-
free conditions and indicated concentratios of S-Lic were investigated by ANOVA followed by 
Dunnett's post-test or Kruskal-Wallis test followed by Dunn's post-test, respectively. 
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Supplementary Table 3: Post-test p-values. Omitted in main text for better readability.
Suppl. Fig. 1  1 s  10 s  30 s
Sham control 0.118 <0.001 0.351
100 µM Post-SE 0.028 0.004 0.669
Comparison 0.097 0.62 0.62
Fig. 2  1 s  10 s  30 s
Sham control 0.034 <0.001 0.012
Post-SE 0.005 <0.001 0.024
Human epilepsy 0.286 0.002 0.108
300 µM Group comparison
Sham vs. post-SE >0.999 >0.999 >0.999
Post-SE vs. human 0.368 >0.999 >0.999
Sham vs. human >0.999 >0.999 >0.999
Fig. 4  -110 mV  -70 mV  -50 mV  -30 mV
Sham control >0.999 0.146 0.089 0.099
Post-SE >0.999 0.057 0.391 0.251
Human epilepsy >0.999 0.271 >0.999 >0.999
30 µM Group comparison
Sham vs. post-SE >0.999 >0.999 0.966 >0.999
Post-SE vs. human >0.999 >0.999 >0.999 >0.999
Sham vs. human >0.999 >0.999 0.774 0.601
Sham control 0.003 <0.001 <0.001 <0.001
Post-SE <0.001 <0.001 <0.001 <0.001
Human epilepsy 0.119 <0.001 <0.001 0.002
100 µM Group comparison
Sham vs. post-SE >0.999 0.627 0.476 0.592
Post-SE vs. human >0.999 >0.999  >0.999  >0.999
Sham vs. human >0.999 0.855 0.68 0.489
Sham control 0.078 <0.001 <0.001 <0.001
Post-SE >0.999 <0.001 <0.001 0.001
Human epilepsy 0.014 <0.001 <0.001 <0.001
300 µM Group comparison
Sham vs. post-SE >0.999 >0.999 >0.999 >0.999
Post-SE vs. human 0.679 0.469 0.255 0.068
Sham vs. human >0.999 0.519 0.32 0.09
Fig. 5  -110 mV  -70 mV  -50 mV  -30 mV
Sham control >0.999 <0.001 <0.001 0.002
100 µM Post-SE 0.028 <0.001 <0.001 0.012
Comparison 0.461 >0.999 0.683 0.214
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2.3 Summary
A highly reduced efficacy of use-dependent blocking of VGSCs by classical AEDs
such as CBZ was demonstrated as a potential mechanism of pharmacoresistance
(Doeser et al., 2014a; Remy et al., 2003a). A previous study reported maintained
S-Lic efficacy on sodium channel fast inactivation processes and on reduction of
repetitive action potential firing when comparing epileptic and nonepileptic tissue
(Doeser et al., 2014a). Recordings in cultured neurons recently indicated potent S-
Lic effects on the modulation of slow inactivation processes (Hebeisen et al., 2015).
Therefore, the aim of the present publication was twofold. The first goal was to
characterize the effects of S-Lic on sodium channel slow inactivation processes in
acutely isolated neurons, using the same approach that identified the loss of CBZ
efficacy in epileptic tissue in previous studies (Doeser et al., 2014a; Remy et al.,
2003a). Secondly and more importantly, the question was asked whether these
effects are lost, reduced or maintained in chronic epileptic tissue.
Putative principal neurons were isolated from the dentate gyrus (and for a subset
of experiments from the sensorimotor cortex) and used for voltage-clamp recordings.
Prolonged depolarizations induced slow inactivation of VGSCs. Application of S-Lic
reduced sodium currents in a dose-dependent manner and enhanced entry into slow
inactivation while the recovery from slow inactivation was unaffected. The voltage
dependence of slow inactivation was investigated by applying a wider range of depo-
larizing or hyperpolarizing prepulses. Whereas for the lowest tested concentration
of S-Lic (30 µM) no significant voltage-dependent effects were observable in DGCs,
100 µM and even more 300 µM evoked significant reductions of sodium current
amplitudes caused by a prominent hyperpolarizing shift of the inactivation curves.
Similar effect sizes were observed in granule cells isolated from the dentate gyrus and
pyramidal neurons of the sensorimoror cortex. Most importantly, no significant dif-
ferences were found when comparing S-Lic effects on cells derived from nonepileptic
control tissue and epileptic rats or TLE patients. Finally, in cultured neurons ex-
pressing individual brain sodium channel isoforms, a subtype-specific blocking effect
of S-Lic was demonstrated.
To conclude, this and previous studies have shown that S-Lic exerts its antiepilep-
tic effects resulting in reduced action potential firing mainly via a hyperpolarizing
shift of the voltage dependence of slow inactivation. This effect is limited to a sub-
set of sodium channel isoforms which might result in a cell-type-specific efficacy.
However, similar S-Lic efficacy was observed between principal cells of the dentate
gyrus and the sensorimoror cortex and importantly also when comparing epileptic
and healthy control cells.
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3 Activity of the anticonvulsant lacosamide in
experimental and human epilepsy via selective
effects on slow Na+ channel inactivation
3.1 Introduction
A series of screening experiments for novel compounds with antiepileptic potency
led to the discovery of functionalized amino acids and subsequently revealed po-
tent anticonvulsant activity in the lead compound lacosamide (LCM), a synthetic
derivative of the endogenous amino acid D-serine (Choi et al., 1996). LCM was ini-
tially approved for adjunctive treatment and more recently as monotherapy of focal
epileptic seizures (Villanueva et al., 2018). In drug interaction studies and clinical
studies, a low interaction profile with other AEDs and drug metabolizing enzymes
was found (Doty et al., 2007). Both, neuroprotective potency following SE but also
neurotoxic effects when combined with valproate or other traditional AEDs were
reported for LCM (Licko et al., 2013; Novy et al., 2011; Stephen et al., 2014).
Mean drug serum levels ranging from 20–80 µM were reported in epilepsy pa-
tients (Greenaway et al., 2011; Sattler et al., 2011). At therapeutic concentrations,
LCM seems to be subject to active transport by drug efflux transporters of the BBB
resulting in brain to plasma ratios between 0.5 in rats and 0.9 in epilepsy patients
(Koo et al., 2011; May et al., 2015; Zhang et al., 2013a). However, intracellular
accumulation of LCM was reported which might facilitate binding to intracellular
portions of VGSCs (Boiteux et al., 2016; Ga´ll and Vancea, 2018). LCM is devoid of
effects on neurotransmitter receptors and ion channels other than VGSCs (Errington
et al., 2006). Controversial results considering interactions with other targets (col-
lapsin response mediator protein 2, carbonic anhydrases or a 14-3-3 protein) were
published and discussed to be unspecific or artificial (Rogawski et al., 2015). LCM
was shown to enhance entry into VGSC slow inactvation and to strongly shift the
slow inactivation voltage dependence in the hyperpolarizing direction by preferen-
tially binding to the channels in their slow inactivated state (Boiteux et al., 2016;
Errington et al., 2008; Hebeisen et al., 2015; Niespodziany et al., 2013; Sheets et
al., 2008). These experiments, however, were mostly conducted in N1E-115 mouse
neuroblastoma cells and did not compare drug effects in nonepileptic and epileptic
tissue and subsequently brought this study into being.
This publication investigates the effects of LCM on fast and slow sodium channel
inactivation processes as well as repetitive action potential firing in DGCs of healthy
and epileptic rats as well as chronic epilepsy patients.
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Activity of the anticonvulsant lacosamide in experimental
and human epilepsy via selective effects on slowNa+
channel inactivation
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SUMMARY
Objective: In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a
major problem affecting ~30% of patients with epilepsy. Many classical antiepileptic
drugs target voltage-gated sodium channels, and their potent activity in inhibiting
high-frequency firing has been attributed to their strong use-dependent blocking
action. In chronic epilepsy, a loss of use-dependent block has emerged as a potential
cellularmechanism of pharmacoresistance for anticonvulsants acting on voltage-gated
sodium channels. The anticonvulsant drug lacosamide (LCM) also targets sodium
channels, but has been shown to preferentially affect sodium channel slow inactivation
processes, in contrast tomost other anticonvulsants.
Methods: We used whole-cell voltage clamp recordings in acutely isolated cells to
investigate the effects of LCM on transient Na+ currents. Furthermore, we used
whole-cell current clamp recordings to assess effects on repetitive action potential fir-
ing in hippocampal slices.
Results: We show here that LCM exerts its effects primarily via shifting the slow inacti-
vation voltage dependence tomore hyperpolarized potentials in hippocampal dentate
granule cells from control and epileptic rats, and from patients with epilepsy. It is
important to note that this activity of LCM was maintained in chronic experimental
and human epilepsy. Furthermore, we demonstrate that the efficacy of LCM in inhibit-
ing high-frequency firing is undiminished in chronic experimental and human epilepsy.
Significance: Taken together, these results show that LCM exhibits maintained
efficacy in chronic epilepsy, in contrast to conventional use-dependent sodium
channel blockers such as carbamazepine. They also establish that targeting slow
inactivation may be a promising strategy for overcoming target mechanisms of
pharmacoresistance.
KEYWORDS: Pharmacoresistance, Epilepsy, Anticonvulsant drugs, Lacosamide.
Chronic epilepsies are a common and serious neurologic
disorder that affects up to 50 million patients worldwide.
About one third of these patients are refractory to currently
available medical treatments. It is therefore important to
understand the cellular mechanisms underlying resistance
to anticonvulsant drugs in order to identify strategies to
overcome drug resistance.
One key candidate mechanism for drug resistance that
has emerged in recent years is an epilepsy-associated
change in the anticonvulsant pharmacology of voltage-
gated Na+ channels.1,2 Voltage-gated Na+ channels are an
important class of therapeutic targets for many anticonvul-
sant drugs, including both classical anticonvulsants and
third-generation antiepileptic drugs (AEDs).3–5 The mecha-
nism of action of most classical anticonvulsants, for
instance carbamazepine (CBZ) or phenytoin, has been
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examined in great detail. It involves pronounced use-depen-
dent blocking effects, in which the development of the block
depends on opening of the Na+ channel.3,4,6 This is likely
because the putative binding site for these and other drugs is
exposed only upon channel opening.6–8 This use-dependent
block has been shown to be reduced in chronic human and
experimental epilepsy in the case of CBZ,1,2 resulting in a
reduced efficacy of this anticonvulsant in inhibiting neu-
ronal firing.9 However, it is clear that a number of new anti-
convulsants exert effects that are markedly different from
those of CBZ. One such anticonvulsant is lacosamide
(LCM), a third-generation AED that is approved as
monotherapy or adjunctive therapy in adults with partial-
onset seizures in the United States. Notably, although many
anticonvulsants do not seem to affect Na+ channel slow
inactivation markedly, LCM shows a pronounced effect on
slow inactivation properties.10,11 LCM seems to exert its
effects primarily via shifting the slow inactivation voltage
dependence to more hyperpolarized potentials.10,11 LCM
also—as shown in previous work—blocks persistent Na+
currents.12 This raises the question if effects of anticonvul-
sants acting on slow inactivation processes are maintained
in chronic human and experimental epilepsy.
We show here that the activity of LCM in modulating
voltage-gated Na+ channels is maintained in chronic experi-
mental and human epilepsy. Furthermore, we demonstrate
that the efficacy of LCM in inhibiting high-frequency firing
is maintained in chronic experimental and human epilepsy.
Materials and Methods
Animal model
All animal experiments were conducted in accordance
with the guidelines of the Animal Care Committee of the
University of Bonn Medical Center. Male Wistar rats (180–
200 g) were housed under a 12-h light/dark cycle with unre-
stricted access to food and water. Rats were injected with a
single high dose of the muscarinic agonist pilocarpine
(340 mg/kg, administered intraperitoneally), which induced
behaviorally detected status epilepticus (SE) in most
(~80%) animals.13–17 Peripheral muscarinic effects were
reduced by prior administration of methyl-scopolamine
(1 mg/kg, administered intraperitoneally [i.p.]; 30 min
before injecting pilocarpine). Diazepam (Ratiopharm:
20 mg/kg, administered subcutaneously) was administered
40 min after onset of SE. It attenuated the SE in the seizing
rats and sedated all animals. Within 24 h after pilocarpine
injection the rats appeared behaviorally normal and were
video-monitored for the development of chronic seizures
starting ~17 days after SE. Only animals that experienced
multiple generalized video-documented seizures were used
for the study.
Human specimens from patients with epilepsy
Surgical specimens were obtained from 16 patients with
therapy-refractory temporal lobe epilepsy (Table S1, age on
average 35.8  2.8 years). The histopathology of most
specimens showed typical features of Ammon’s horn scle-
rosis (11 specimens). One specimen (P6) showed a develop-
mental malformation, and one further specimen a
cavernoma (P7). Most patients had complex partial and sec-
ondary generalized seizures. Studies on human material
were approved by the institutional research ethics commit-
tee. Appropriate consent was obtained from human subjects
for use of the material.
Animal preparation
Animals were perfused through the heart under deep
anesthesia (ketamine 100 mg/kg, xylazine 15 mg/kg) 28–
49 days after SE with ice-cold sucrose-based artificial CSF
(ACSF) comprising (in mM): NaCl 60, sucrose 100,
NaHCO3 26, KCl 2.5, NaH2PO4 1.25, MgCl2 5, CaCl2 1,
and glucose 20, pH 7.4, osmolality 305 mOsmol. Subse-
quently the brain was rapidly removed. The time from pilo-
carpine injection to the experiment was 49.5  3.9 days.
Animal and human slice and dissociated cell preparation
Transverse hippocampal slices (rat: 300 lm, human:
400 lm) were prepared with a vibrating microslicer
(VT1200S; Leica) in carbogenated sucrose ACSF (95% O2,
5% CO2). For rat tissue, the same sucrose-based ACSF as
for perfusion was used; for human tissue it had the following
composition (in mM): NaCl 87, sucrose 75, NaHCO3 25,
KCl 2.5, NaH2PO4 1.25, MgCl2 7, CaCl2 0.5, and glucose
25. Immediately after their preparation, human hippocam-
pal slices were stored in ACSF containing (in mM) NaCl
124, KCl 3, MgCl2 2, CaCl2 2, NaHCO3 26, NaH2PO4 1.25,
and glucose 10. Rat slices, however, were first transferred to
a storage chamber filled with sucrose-based ACSF, gradu-
ally warmed to 35°C in a water bath, and maintained at this
temperature for ~20 min. Finally, all slices were transferred
into a chamber filled with ACSF containing the following
(in mM): NaCl 125, KCl 3.5, MgCl2 2, CaCl2 2, NaHCO3
26, NaH2PO4 1.25, and glucose 15, pH 7.4, osmolality
Key Points
• LCM reduces sodium current amplitude strongly
• LCM has large effects on the voltage dependence of
slow inactivation, with only small effects on other
sodium current properties
• LCM activity on voltage dependence of slow inactiva-
tion and neuronal firing is maintained in experimental
and human epilepsy
• Sodium channel blockers targeting slow inactivation
processes may be a promising strategy for overcoming
target mechanisms of pharmacoresistance
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307 mOsmol, where they stayed at room temperature for an
equilibration period of at least 30 min until they were used
for recording or preparation of dissociated cells.
For the preparation of dissociated granule cells, one slice
at a time was put into trituration solution (in mM): Na
methanesulfonate 145, KCl 3, CaCl2 0.5, MgCl2 1, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
10, glucose 15, pH 7.4 adjusted with NaOH, osmolality
315 mOsmol, mixed with pronase (protease type XIV,
2 mg/ml; Sigma) under constant supply with oxygen
(100%) for 12 min at 36°C. After an equilibration period of
10 min at room temperature, slices were washed in pronase-
free solution. Subsequently, the dentate gyrus was dissected
and triturated with fire-polished Pasteur pipettes of decreas-
ing aperture in a Nunc Dish (3.5 cm; Thermo Scientific)
filled with bath solution (see bath solution described below
for isolated cells). Cells were allowed to settle for at least
10 min before start of the patch-clamp experiments.
Whole-cell patch-clamp analysis of neuronal firing
behavior
Action potential firing was recorded from rat or human
dentate gyrus granule neurons. Cells were visualized using
a Zeiss Axioskop upright microscope equipped with infra-
red difference interference contrast optics and a water-
immersion lens (609, 0.9 NA; Olympus). Somatic whole-
cell current-clamp recordings were made with a BVC-
700A amplifier (Dagan) run in bridge mode. Data were
sampled at 10 kHz (8 s current injection) and 100 kHz
(3 msec and 8 s current injections) with a Digidata 1322A
or 1440A interface controlled by pClamp software
(Molecular Devices). Patch pipettes were pulled from
borosilicate glass capillaries (0.86 mm inner diameter,
1.5 mm outer diameter, with filament; Science Products)
with a micropipette puller (PP-830; Narishige). Electrode
resistance in the bath ranged from 3 to 7 MΩ. The inter-
nal solution contained the following (in mM): K-gluconate
127, KCl 20, HEPES 10, ethylene glycol-bis (2-ami-
noethylether)-N,N,N0,N0-tetraacetic acid (EGTA) 0.16,
Mg-ATP 4, Na2-ATP 2, D-glucose 10 (pH adjusted to
7.25 with KOH, 295 mOsmol). The extracellular ACSF
was identical to that used for slice storage (31°C). Mem-
brane potential was corrected offline for a liquid junction
potential of 14.0 mV.
Data analysis, current clamp experiments
The voltage traces recorded in current clamp mode were
analyzed with custom routines in Igor Pro (Wavemetrics).
Action potentials were described quantitatively by deter-
mining their peak amplitude, the maximal rate of rise of the
voltage trace, the action potential threshold, and the width at
the voltage level halfway between threshold and peak. The
action potential threshold was determined as the voltage at
which the slope of the voltage trace (dV/dt) exceeded
15 mV/msec. Repetitive firing was examined using
prolonged current injections (8 s). Input–output relations
were obtained with an automatic action potential detection
routine programmed in Igor Pro. For analysis of use depen-
dence, only traces with action potential firing throughout
the entire duration of depolarization (8 s) were used. The
traces were then divided into eight bins of 1 s each, and the
maximal dV/dt for all action potentials within the same time
bin was averaged. To examine the effect of LCM, traces
were selected to exhibit approximately the same number of
action potentials during baseline, LCM application, and
washout.
Patch-clamp analysis of Na+ currents in isolated neurons
For recording transient Na+ currents (INaT), the trituration
solution was exchanged with bath solution (in mM): Na-
methanesulfonate 40, tetraethylammonium-Cl 90, CaCl2
1.6, MgCl2 2, HEPES 10, CdCl2 0.2, 4-aminopyridine 5,
glucose 15, pH 7.4 adjusted with HCl; osmolality
310 mOsmol, adjusted with glucose. The Nunc dish was
then mounted on an inverted microscope (Axiovert 100;
Zeiss) and constantly superfused with bath solution. Patch
pipettes were pulled from borosilicate glass capillaries as
stated above with a micropipette puller (Model P-97; Sutter
Instruments & Co) and filled with intracellular solution (in
mM): CsF 110, HEPES-Na 10, EGTA 11, MgCl2 2, TEA-Cl
20, Na2-GTP 0.5, ATP-Na2 5, pH 7.25 adjusted with CsOH;
osmolality 300 mOsmol. Only pipettes with a resistance of
4.5–6.5 MΩ were used for the experiments. Tight-seal
whole-cell recordings were obtained with a seal-resistance
of >1 GΩ using a patch-clamp amplifier (Axopatch 200B;
Molecular Devices). Series resistance was 6.4  0.3 MΩ
for rat recordings and 6.6  0.7 for human recordings, and
could be compensated between 70 and 90%. Maximal resid-
ual voltage error was 5.3  0.4 mV for rat recordings and
5.0  0.6 for human recordings. Currents were filtered at
10 kHz, sampled at 50 kHz with a Digidata 1440A and
recorded by a personal computer using the Clampex 10.2
acquisition software (Molecular Devices). In addition, all
command and measured voltages were corrected for the liq-
uid junction potential (10.0 mV).
Data analysis, voltage-clamp experiments
The conductance G(V) was calculated according to:
GðVÞ ¼ IðVÞ=ðV VNaÞ;
where VNa is the Na
+ reversal potential, V the command
potential, and I(V) is the peak current amplitude. In addi-
tion, G(V) was then fitted with the following Boltzmann
equation:
GðVÞ ¼ A1 þ ðA1  A2Þ=ð1þ eðVV50Þ=kÞ:
A1 and A2 are sodium conductances, V50 is the voltage
where G(V) reaches its half-maximal value, and k indicates
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the slope of the relation between channel activation or inac-
tivation and membrane voltage.
Double-pulse experiments to examine recovery from fast
inactivation were analyzed in the following way. First the
current amplitudes obtained during the test-pulse were nor-
malized to the amplitudes obtained during the conditioning
pulse. The curve resulting from a plot of the maximal ampli-
tude against the corresponding time interval was best
described by a bi-exponential equation:
IðtÞ ¼ A0 þ Afast1  et=s fast1 þ Afast2  et=s fast2;
where I(t) is the normalized current amplitude at the time-
point t after onset of the voltage command, Afast1 and
Afast2 are the relative amplitude contributions of the two
recovery time constants sfast1 and sfast2, respectively, and
A0 is a constant offset. Recovery from slow inactivation
was fitted with an equivalent equation, with the time con-
stants of slow recovery denoted sslow1 and sslow2. Fitting
was done using a Levenberg-Marquardt algorithm. Data
for recovery from slow inactivation were fitted with
equivalent methods.
Pharmacology, compounds, and stock solutions
LCM and CBZ were prepared as stock in ethanol and
added to the bath 1:1,000. Control ACSF included equal
concentrations of ethanol. In general baseline and wash val-
ues were averaged for all protocols, termed “ACSF” and
compared to a single “LCM” value. For estimating the
LCM-induced reduction of INaT, control values were gener-
ated by averaging the current amplitudes immediately
before washin and immediately after washout as a control
current amplitude. These were related to the average of the
current amplitude immediately after saturation of the LCM
effect and the current amplitude immediately before starting
washout.
Statistical analysis
For statistical comparison the Student’s t-test at a signifi-
cance level a of 0.05 was used, if appropriate a paired t-test
was applied. In some instances, analysis of variance
(ANOVA) was used with an appropriate posttest mentioned
in each individual experiment. If assumptions for an
ANOVA were not met, appropriate nonparametric methods
were used which are also indicated for each individual sta-
tistical comparison. Results are always presented as
mean  standard error of the mean (SEM).
Results
LCM reduces voltage-gated Na+ current amplitude in
experimental and human epilepsy
We systematically compared the effects of LCM on
granule cells isolated from brain slices of control animals
to those of animals who experienced status epilepticus
(SE) following intraperitoneal administration of pilo-
carpine and who subsequently showed spontaneous sei-
zures (see Materials and Methods). We used an initial test
concentration of 100 lM LCM. We first applied LCM
while delivering brief depolarizations from a holding
potential of 90 mV (to 30 mV, 15 msec). To assess
the magnitude of LCM effects, data points obtained under
control conditions and after washout of LCM were aver-
aged to generate a single control value for each cell, to
which the current magnitude after saturation of the LCM
effect was compared. This analysis revealed a consistent
reduction of peak INaT by 41.1  3.0% and 41.5  4.7%
in sham-control and pilocarpine-treated animals, respec-
tively (Fig. 1A,C, n = 6 and 7). A rundown of peak INaT
was apparent in these recordings. We therefore performed
experiments exactly as described, but omitted LCM from
the perfusate (ACSF control application). Calculating the
magnitude of effects of the ACSF control application as
for LCM effects (LCM shown in Fig. 1C) yielded a
Figure 1.
Robust reduction of peak transient Na+ current (INaT) significant shifts in inactivation gating in dentate gyrus granule cells by LCM. (A) INaT
was elicited with brief depolarizations from a holding potential of90 mV (left). Currents were obtained in control solution, after appli-
cation of 100 lM LCM just before washout, and after stabilization of washout (black, orange, and blue traces, respectively). Representative
examples shown for sham-control and epileptic (post-SE) animals. (B) Representative examples of LCM effects (also 100 lM) on a human
isolated granule cells. Line colors as in panel A. (C) Average reduction of peak sodium currents in sham-control and pilocarpine-treated
animals, as well as human granule cells (n = 6, 7 and 6). (D) Transient Na+ current (INaT) was elicited by depolarizing pulses from a
90 mV holding potential to various test potentials (a), followed after 500 msec by a brief step to 30 mV (b). Example traces of INaT
recorded at the indicated time points in the protocol (left panel) to assess channel activation (a) and inactivation (b). Example from a
sham-control animal. (E) INaT was converted to conductance and normalized to the cell’s maximal conductance. Plots summarize LCM
effects (100 lM) in sham-control and pilocarpine-treated (post-SE) rats (n = 6 each). (F) Effects of LCM on voltage-dependence of INaT in
dentate gyrus granule cells isolated from human brain tissue (n = 9). (G,H) Summary of LCM effects on the potential of half-maximal INaT
activation (G) and inactivation (H). Asterisks in panel E indicate p < 0.001, 0.006, and 0.006 for sham-control, post-SE and human groups,
respectively, paired t-test). (I) Summary of the shift in V50 of activation and inactivation seen in sham-control and epileptic animals, as well
as granule cells obtained from patients with TLE.
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negligible effect of sham ACSF application (0.6  1.4%
and 1.4  1.5% for control and pilocarpine-treated rats,
respectively, n = 7 and 3).
We next examined effects of 100 lM LCM on the proper-
ties of INaT in human isolated granule cells from epileptic
patients (Fig. 1B) using the same stimulation protocol.
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These recordings also revealed a robust reduction of peak
Na+ currents by 49.8  4.3% (Fig. 1C, n = 6). The magni-
tude of the blocking effects was not significantly different
between any of these three groups (Kruskal-Wallis test,
n.s.).
LCM effects on steady state voltage-dependence
We then examined the voltage-dependence of INaT
under control conditions, after washin of LCM, and after
washout using standard protocols. Voltage steps ranging
from 120 to 25 mV were applied, followed by a con-
stant voltage step to 30 mV (Fig. 1D). The first of the
two steps causes activation of INaT, allowing analysis of
the voltage-dependence of activation. The steady-state
inactivation was examined by evaluating the peak Na+ cur-
rent during the second voltage step to 30 mV, and deter-
mining how much of this current is inactivated due to the
first voltage step (Fig. 1D, traces labeled with lowercase
b). As in Figure 1C, data points obtained under control
conditions and after washout of LCM were averaged to
generate a single control dataset for each cell. Fitting with
a modified Boltzmann equation to describe the voltage
dependence of the conductance revealed no effects of
100 lM LCM on the voltage-dependence of activation
(Fig. 1E,G). We observed small but significant effects on
the voltage-dependence of inactivation, manifesting in a
small hyperpolarizing shift of the voltage of half-maximal
inactivation (Fig. 1E,H, shift of 4.3  0.4 and
4.4  1.3 mV in sham-control and pilocarpine-treated ani-
mals, respectively, n = 6 for both groups, ***p < 0.001,
**p = 0.006, paired t-test).
Similar results were obtained for human epileptic granule
cells. One hundred micromolar LCM had no effects on the
voltage-dependence of activation, but had a small hyperpo-
larizing effect of the voltage of half-maximal inactivation
(Fig. 1F–I, shift of 2.8  0.8 mV, **p = 0.006, paired
t-test). The magnitude of the LCM effects was not different
between any group (Fig. 1I, Kruskal-Wallis test, n.s.). Thus,
small effects on inactivation voltage-dependence exist in
both experimental and human epilepsy. However, these
shifts do not explain the large reduction in peak Na+ currents
observed in Figure 1A–C.
LCM effects on recovery from fast inactivation
In the pilocarpine model of temporal lobe epilepsy, a dis-
tinctive loss of CBZ effects on the recovery behavior was
observed, both in the pilocarpine model of epilepsy and in
patients with therapy-refractory epilepsy. This raises the
question if LCM shows reduced or maintained effects in
chronic experimental epilepsy. We examined the recovery
from fast inactivation using standard protocols, both in con-
trol and pilocarpine-treated animals (Fig. 2A). Two brief
depolarizations of 15 msec (30 mV) were applied with a
varying interpulse interval of 1–8,192 msec, and a holding
potential of 90 mV. Plotting the magnitude of the
normalized current during the second of the two depolariza-
tions versus the interpulse interval allows evaluation of the
recovery from fast inactivation. The time course of recovery
did not reveal large effects of 100 lM LCM (n = 6 and 7,
Fig. 2B). However, fitting the time course did show a small
significant effect of LCM in control rats (30.1% increase of
the time constant of fast recovery, ***p < 0.001, paired
t-test, Fig. 2D). In human dentate granule cells, there was
no effect of 100 lM LCM on fast recovery (n = 9, Fig. 2C,
D). There were, however, no significant differences
between control and epileptic rats as well as human speci-
mens regarding the effects of LCM (Fig. 2E, Kruskal-
Wallis test, n.s.).
Effects of LCM on Na+ channel slow inactivation in
experimental and human epilepsy
The experiments so far show a robust reduction of Na+
channel conductance (see Fig. 1A–C), which is not easily
explained by effects of LCM on voltage-dependence or
recovery from fast inactivation. We therefore next exam-
ined the effects of LCM on slow inactivation of Na+ chan-
nels in rat and human dentate gyrus granule cells. In these
experiments, entry of Na+ channels into slow inactivation
was induced by holding neurons for 1, 10, or 30 s at a depo-
larizing membrane potential (30 mV). The membrane
potential was then returned to 90 mV for 1-s to allow
complete recovery from fast inactivation (Fig. 3A). This
allows determination of the magnitude of the remaining
slow inactivation. The fraction of channels entering slow
inactivation can be quantified by comparison of the peak
Na+ channel amplitude during the test pulse to the amplitude
obtained with the conditioning pulse (black vs. red lines in
Fig. 3B, examples shown for sham-control and pilocarpine-
treated rats and epilepsy patients as indicated). This allowed
us to assess the effects of LCM on the time course of entry
into slow inactivation.
As expected, prolonging the conditioning pulse from 1 to
30 s resulted in a marked increase in channels undergoing
slow inactivation, both in sham-control animals and in pilo-
carpine-treated animals (Fig. 3B, compare black vs. red
lines, n = 7 and 6). Small but statistically significant
increases in the fraction of channels entering slow inactiva-
tion during the depolarizing prepulse were observed after
application of 100 lM LCM (Fig. 3C, two-way ANOVA,
sham control: F1,15 = 20.3, p < 0.001, pilocarpine-treated:
F1,15 = 4.9, p = 0.04, followed by Bonferroni posttest for
LCM efficacy with **p < 0.01). In human dentate granule
cells, the results were very similar, with an also small but
significant enhancement of entry into slow inactivation by
100 lM LCM (Fig. 3C, lower panel, n = 9, two-way
ANOVA, F1,24 = 19.3, p < 0.001, followed by Bonferroni
posttest for LCM efficacy with **p < 0.01). There were no
significant differences between control and epileptic rats as
well as human specimens regarding the effects of LCM
(Fig. 3D, Kruskal-Wallis test, n.s.).
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Figure 2.
Effects of LCM on recovery from fast inactivation of Na+ channels in dentate gyrus granule cells. (A) Sample traces illustrating recovery
from fast inactivation elicited by the voltage step protocol displayed in the inset. INaT was elicited by pairs of brief 15 msec depolarizing
pulses from90 mV holding to30 mV test potential. The interval between the two pulses was varied from 1 msec up to 8,192 msec in
increments of 2n. This stimulation protocol was applied three times to every neuron tested: under baseline condition, after application of
100 lM LCM, and after a washout period. Baseline and washout data were averaged for comparison to 100 lM LCM. (B) Summary of
experiments in sham-control and pilocarpine-treated (post-SE) rats (n = 6 and 7, respectively). (C) Summary of experiments in granule
cells from TLE patients (n = 9). (D) Quantification of the kinetics of recovery from fast inactivation. The time constant of fast recovery
(sfast) was obtained by fitting the individual recovery time courses. A small but significant increase of sfast was found only for control rats
(asterisks indicate p < 0.001, paired t-test). (E) Quantification of the magnitude of LCM effects on sfast.
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We then examined the time course of recovery from slow
inactivation, which was monitored starting 1 s after return-
ing the holding potential to 90 mV with brief (15 msec)
test pulses to 30 mV every 3 s (Fig. 3E, examples shown
in Fig. S1B for sham control and epileptic animals, n = 7
and 6, respectively, left panels). The average time course of
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recovery with prepulse durations of 30 s is depicted in Fig-
ure 3F. The time course of recovery from slow inactivation
was fit with a biexponential equation. No significant effects
of 100 lM LCM were observed (Fig. 3G, Wilcoxon
matched-pairs test, Fig. 3H,I, paired t-test). In human den-
tate granule cells, LCM also had no significant effects on
the dynamics of slow recovery from inactivation (Fig. 3F,
lower panel, example in Fig. S1C). There were no signifi-
cant differences between control and epileptic rats as well
as human specimens regarding the effects of LCM
(Fig. 3G–I, Kruskal-Wallis test, n.s.).
For conditioning prepulses shorter than 30 s, it proved
difficult to obtain consistent fitting of the second, ultra-slow
component of slow recovery, as these components become
very small and are contaminated by run-down over the time
course of long-duration pharmacologic experiments. We
therefore focused on the recovery from robust inactivation
induced by 30 s prepulses, and refrained from further
analyzing recovery from inactivation induced by shorter
prepulses.
Potent effects of LCM on the voltage-dependence of slow
inactivation in experimental and human epilepsy
Our results so far show only small effects of LCM on the
biophysical properties of Na+ channels related to fast-inacti-
vation processes. They also revealed small effects of LCM
on the kinetics of slow inactivation. This raises the question
of why we observe a robust decrease of Na+ currents elicited
with holding potentials of90 mV (see Fig. 1). These find-
ings would be consistent with a hyperpolarizing shift of the
voltage dependence of slow inactivation, as observed in pre-
vious studies.10,11 We, therefore, assessed entry into slow
inactivation with different prepulse potentials. We used
10 s prepulses to voltages of110 to50 mV as condition-
ing prepulses to induce entry into slow inactivation. Values
for 30 mV were derived from the previous recordings of
slow inactivation (Fig. 4A). These results show a voltage-
dependence of slow inactivation, with increasing fractions
of the Na+ channels inactivated at increasingly depolarized
prepulse potentials (Fig. 4B, n = 7 and n = 6 for sham-con-
trol and pilocarpine-treated animals, respectively). One
hundred micromolar LCM caused a strong reduction of Na+
current amplitudes that was voltage-dependent (Fig. 4B,
two-way ANOVA, sham control: F1,30 = 558.1, p < 0.001,
pilocarpine-treated: F1,27 = 96.96, p < 0.001, followed by
Bonferroni posttest for LCM efficacy with **p < 0.01 and
***p < 0.001). These effects of LCM were not different
when comparing sham-control and epileptic animals
(Fig. 4D, Kruskal-Wallis test, n.s.). The voltage-dependent
effects were not contaminated by run-down problems, as
became clear when recordings were performed exactly as
described in Figure 4, but omitting LCM from the perfusion
solution (see Fig. S2). We next performed identical experi-
ments in human dentate granule cells (n = 6). Also here,
100 lM LCM had potent effects on the voltage-dependence
of slow inactivation (Fig. 4C, two-way ANOVA,
F1,28 = 238.7, p < 0.001, followed by Bonferroni posttest
for LCM efficacy with **p < 0.01 and ***p < 0.001) simi-
lar to those seen in sham-control or epileptic animals
(Fig. 4D, Kruskal-Wallis test, n.s.).
In contrast to the dominant effects of many Na+ channel–
acting anticonvulsants on voltage-dependence and recovery
from fast in activation, the major effects of LCM are on the
voltage-dependence of slow recovery from inactivation.
This effect causes a robust reduction of Na+ currents elicited
from holding potentials between 110 and 50 mV. It is
important to note that these effects of LCM are completely
unchanged in chronic epilepsy, and are also present to a
quantitatively similar extent in cells from human epileptic
patients.
Effects of LCM on repetitive firing in experimental and
human epilepsy
Based on the pronounced effects of LCM on slow inacti-
vation we speculated that the effects of LCM on neuronal
firing should also be maintained in chronic epilepsy, in
Figure 3.
LCM effects on entry into and recovery from slow inactivation of Na+ channels in rat and human dentate gyrus granule cells. (A) Voltage
step protocol used to analyze entry of Na+ channels into slow inactivation. The membrane was depolarized from 90 to 30 mV for
variable durations and then returned to 90 mV for 1 s to allow complete recovery from fast inactivation before recording a brief
(15 msec) test pulse. (B) Representative examples for currents elicited by 1, 10, and 30 s conditioning pulses (black lines) and respective
test pulses (red lines) for granule cells from sham-control and pilocarpine-treated rats as well as TLE patients. Traces are depicted under
baseline conditions (top row) and after application of 100 lM LCM (bottom row). (C) Summary of test pulse amplitudes normalized to
conditioning pulse amplitudes in sham-control and pilocarpine-treated rats (n = 7 and 6) as well as TLE patients (n = 9). Values during
application of 100 lM LCM and the averages of baseline and washout conditions are shown. Asterisks indicate significant differences of
Bonferroni posttest indicated with **p < 0.01. (D) Summary of the relative magnitude of effects on entry into slow inactivation. (E) Volt-
age step protocol used to analyze recovery of Na+ channels from slow inactivation. Starting 1 s after the conditioning pulse, test pulses
(15 msec) at 3 s intervals were used for determining the time course of recovery from slow inactivation. (F) Time course of test pulse
amplitudes normalized to the amplitude of the conditioning pulse for granule cells isolated from sham control and pilocarpine-treated rats
or TLE patients. LCM indicates data points corresponding to washin of 100 lM LCM (orange); ACSF indicates data points from an average
of baseline and washout data (white). (G–I) Quantification of the time course of recovery from slow inactivation. PanelsH and I denote
the slow and ultra-slow time constants of recovery. PanelG depicts the fraction of current recovering with the slow time constant sslow.
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contrast to, for example, CBZ.1,9 We therefore next exam-
ined effects of LCM on action potential firing in rat and
human dentate granule cells. We first obtained patch-clamp
recordings from hippocampal dentate granule cells in the
slice preparation in sham-control and pilocarpine-treated
rats (see Materials and Methods), and elicited neuronal fir-
ing with current injections of different magnitude (Fig. 5A).
In these recordings, the membrane potential was not
clamped, but was uniformly at 86.9  0.9 mV in sham-
control and 84.4  0.9 mV in pilocarpine animals
(n = 11 for both groups, n.s.). The maximal firing frequen-
cies obtained without LCM in sham versus pilocarpine-trea-
ted animals were not different (26.2  2.5 vs.
25.7  1.9 Hz). There were also no clear differences in
Figure 4.
LCM effects on voltage-dependence of slow inactivation of Na+ channels in dentate gyrus granule cells. (A) Voltage step protocol used to
analyze voltage-dependence of slow inactivation. A brief test pulse (15 msec to30 mV) was followed by conditioning pulses to potentials
ranging from110 to50 mV (10 s). Another test pulse (15 msec) was applied after recovery from fast inactivation 1 s after the end of
the conditioning pulse. (B, C) Summary of test pulse amplitudes normalized to the test pulse of the corresponding 110 mV recording.
Amplitudes for30 mV were derived from the previous recordings of slow inactivation. A comparison of averaged baseline and washout
amplitudes (white symbols) to those of 100 lM LCM (orange symbols) shows a significant and very pronounced reduction of sodium cur-
rents both in rat (B) and human (C) granule cells. (n = 7, 6 and 6 for sham-control and pilocarpine-treated animals, and human granule
cells, respectively. For Bonferroni posttests, ** and *** indicate significance levels of p < 0.01 and p < 0.001, respectively). (D) Summary
of the effects of LCM at different conditioning pulse potentials.
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Figure 5.
Effects of LCM on repetitive action potential firing of rat and human dentate gyrus cells. (A, B) Representative voltage traces elicited by cur-
rent injections at threshold for eliciting firing, as well as 29 and 39 threshold current injection. Data are shown for sham-control rats and pilo-
carpine-treated rats (A) and patients with TLE (B). Current injection steps are depicted in the bottom row. (C, D) Input–output diagrams
illustrate the action potential frequency plotted against injected current for sham control and pilocarpine-treated (C, n = 11 for both groups)
and human granule cells (D, n = 9). Average firing frequency was assessed during the consecutive application of 30 lM (yellow symbols) and
100 lM LCM (orange symbols) and compared to the average values of preapplication (ACSF) and postapplication (wash) period (white sym-
bols). (E) Inhibitory effects of different concentrations of LCM on repetitive firing. A significant reduction of action potential frequency was
found in all three experimental groups for concentrations ≥100 lM (asterisks omitted for clarity, Dunnett multiple comparison test, p < 0.01).
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input-output relationships between these groups (c.f.
Fig. 5C, left vs. right panel).
LCM application induced a reversible, dose-dependent
inhibition of firing in both sham-control animals and pilo-
carpine-treated animals, as revealed in the input–output
curves of firing frequency versus current injection magni-
tude (Fig. 5A,C). The effects on the firing rate observed at
300 pA current injections were significant for concentra-
tions of LCM >100 lM (one-way ANOVA, sham control:
F3,47 = 18.41, p < 0.001, pilocarpine-treated: F3,42 = 5.77,
p = 0.002, followed by Dunnett posttest for LCM efficacy).
Thus, these results show that while CBZ exhibits reduced
effects on repetitive firing,9 LCM effects are maintained in
chronic experimental epilepsy.
We next examined if LCM is capable of efficiently
modulating neuronal excitability and firing behavior in
human epilepsy. We obtained whole-cell patch-clamp
recordings from human dentate granule cells in the slice
preparation, and examined their firing behavior during
prolonged (8 s) current injections. Again, the effects on
the firing rate observed at 300 pA current injections were
significant for 100 lM LCM (one-way ANOVA,
F2,16 = 5.91, p = 0.012, followed by Dunnett posttest for
LCM efficacy). The effects of LCM on human dentate
granule cells was indistinguishable from control or epilep-
tic rat dentate granule cells (Fig. 5B,D,E, Kruskal-Wallis
test, n.s., for 100 lM LCM).
Effects of LCM on action potential properties in
experimental epilepsy
We next examined the use-dependent effects of 100 lM
LCM on action potential generation of dentate gyrus neu-
rons in more detail. We selected traces under baseline con-
ditions, 100 lM LCM and after wash that had
approximately the same numbers of action potentials
(Fig. 6A, uppermost traces, example from a control ani-
mal). This strongly underestimates the effects of LCM on
neuronal firing, but allows examination of how action
potential parameters change systematically with and with-
out LCM during prolonged firing.
Plotting the rate of the membrane potential change (dV/
dt) versus membrane potential (Vm; shown for the traces in
the upper row, Fig. 6A) for representative action potentials
at the onset of firing, in the middle of the current injection,
and at the end of the current injection revealed systematic
changes in the action potential waveform. No large changes
of action potential waveform were observed for the first
action potential (black curves). Successively larger effects
of 100 lM LCM were found for the middle and last action
potentials in the train (orange and blue curves, respectively),
consistent with a slowly evolving block of Na+ channels
during prolonged firing (Fig. 6A, lower panels). A detailed
summary of action potential properties as well as passive
properties can be found in Table S2 (for statistics see Tables
S3 and S4).
Plots of the first derivation of Vm binned in 1 s time bins
over the time course of the current injection confirmed this
impression in sham-control and epileptic rats (Fig. 6B,
n = 11 and 17, respectively) and human granule cells
(Fig. 6C, n = 5, limited to those cells in which sweeps with
persistent firing under LCM could be identified). LCM
application led to a significantly stronger decrease in maxi-
mal dV/dt during the current injection compared to control
conditions in all groups (Fig. 6D, ***p = 0.001 for both rat
groups and *p = 0.03 for human cells, respectively, paired
t-test). The magnitude of this use-dependent effect was not
different between the groups (n.s., Kruskal-Wallis test).
Discussion
The main result of this study is that LCM acts mainly via
effects on the voltage-dependence of slow inactivation in
native human and rat neurons. Moreover, the efficacy of
LCM is maintained in chronic human and experimental epi-
lepsy, unlike the conventional use-dependent blocker CBZ.
Our results in native human and rat neurons are in line
with the previous studies in primary neocortical cul-
tures,10,11 also showing a potent shift of the voltage-depen-
dence of slow inactivation in a hyperpolarizing direction by
LCM. The effects on the time course of entry or recovery
from slow inactivation were, in contrast, small or nonsignif-
icant.10 In this previous study, no effects on fast inactivation
properties were seen. This is dissimilar to our results, in
which we did observe small but significant effects of LCM
Figure 6.
Use-dependent effects of 100 lM LCM on action potential generation of dentate gyrus neurons. (A) Upper panel: Examples of represen-
tative traces selected for this analysis under baseline conditions, 100 lM LCM and after wash (control animal) with approximately the
same numbers of action potentials. Middle panel: Representative action potentials at the onset of firing (black), in the middle of the cur-
rent injection (orange), at the end of the current injection (blue), and the respective first derivations of the voltage trace (small traces).
Lower panels: Plots of the rate of the membrane potential change (dV/dt) versus membrane potential (Vm) for the traces in the middle
panels. (B,C) Plots of the first derivation of Vm binned in 1 s time bins over the time course of the current injection in sham-control and
epileptic rats (B) and human granule cells (C). All data are normalized to the dV/dt values obtained in the first time bin. (D) Change in dV/
dt over the duration of the current injection under control conditions and after LCM application. For paired t-tests of dV/dt differences
between first and last time bins, * and *** indicate significance levels of p < 0.05 and p < 0.001, respectively. Values are illustrated as %
reduction of the initial dV/dt.
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on inactivation voltage dependence. This may be ascribed
to the fact that these are native neurons from adult animals,
with very different Na+ channel properties. In addition, it is
possible that the prepulses used to invoke inactivation
(0.5 s) cause a small amount of slow inactivation that might
contribute to this effect. Nonetheless, the effects that these
shifts in half-maximal fast inactivation have on the avail-
ability of Na+ channels were—in contrast to the large effects
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on slow inactivation voltage-dependence—negligible. The
effects on neuronal firing that we observed were also largely
consistent with data obtained in cultured neurons.10,18 These
studies already show effects of LCM on repetitive firing that
were most pronounced with long (10 s) current injections.10
In our hands, this was similar, with large effects on firing
being observed with prolonged current injections. We also
observed effects already at low (30 lM) concentrations of
LCM, which were markedly increased at higher concentra-
tion (100 and 300 lM), likewise consistent with Errington
et al.10
The voltage-gated Na+ channel seems to be the major tar-
get for LCM, as binding studies have excluded binding of
LCM to different types of c-aminobutyric acid (GABA) and
glutamate receptors, as well as a variety of other neurotrans-
mitter receptors, and voltage-gated potassium or calcium
channels.18 Likewise, there was no physiologic effect of
LCM on GABA and glutamate receptors, neurotransmitter
transporters, or GABA metabolism.18,19 These results con-
firm in native adult neurons that the mechanism of action of
LCM on Na+ channels is very different from classical use-
dependent Na+ channel blockers, such as carbamazepine or
phenytoin.
This raises the question if the effects of LCM are also lost
in chronic epilepsy, which has been shown for use-depen-
dent effects of CBZ in the same model in granule cells.1
Similarly, an impairment of sodium current modulation by
CBZ but not valproic acid has been reported in patients with
TLE as well as in the kindling model.20,21 The answer, at
least for LCM in dentate granule cells, is an unequivocal no.
We observed quantitatively maintained effects of LCM on
slow inactivation in experimental epilepsy. Moreover, we
found that Na+ channels in granule cells obtained from epi-
lepsy surgical specimens were strongly inhibited by LCM,
with quantitatively similar, selective effects on the slow
inactivation voltage-dependence. These maintained effects
of LCM translated into potent inhibition of repetitive firing
induced by long current injections in both experimental and
human epilepsy. It would be interesting to examine if effects
on slow inactivation are maintained in this and perhaps
other brain regions that show decreases in anticonvulsant
actions on parameters of fast sodium channel inactivation.
Taken together, these results suggest that LCM effects are
conserved in chronic epilepsy.
What does this finding mean for the key goal of overcom-
ing pharmacoresistance? A previous study has shown that
the active metabolite of the anticonvulsant eslicarbazepine
has potent use-dependent effects in experimental and human
epilepsy, and in fact has add-on effects to CBZ.9 The molec-
ular mechanism for this effect is unknown, but this article
suggested that one way to overcome pharmacoresistance is
to design drugs that exhibit maintained use-dependent block
on Na+ channels in chronically epileptic tissue.9 The present
study suggests a viable alternative—to use compounds that
do not exert their effects via use-dependent block, but rather
act on slow inactivation. These results also may impact
thinking about combining classical use-dependent Na+
channel blockers with compounds such as LCM. Although
targeting the same ion channel protein, the compounds have
very different mechanisms of action, and add-on treatment
with LCM in the presence of conventional Na+ channel
blockers should not be discounted due to mechanistic con-
siderations alone.
In addition to changes in the pharmacology of Na+
channels in chronic epilepsy, a further candidate mecha-
nism that may underlie pharmacoresistance is an altered
expression of multidrug transporters in chronic epilepsy.
An upregulation of drug transporters occurs in different
types of chronic experimental and human epilepsies, and
affects anticonvulsant drug concentrations present in the
central nervous system (CNS) parenchyma. The capability
of different members of the multidrug transporter family
to transport anticonvulsants has been addressed in several
publications. These have revealed that multidrug trans-
porters effectively transport many, but not all, anticonvul-
sant drugs. It has been shown that LCM is a substrate for
transport by human P-glycoprotein, which is one of the
most consistently upregulated drug transporters in chronic
epilepsy.22 However, this work also revealed that passive
diffusion appears to be a major component of LCM distri-
bution. Thus, the role of active transport in the disposition
of LCM in vivo is unclear. However, should LCM prove
to be subject to active transport, it might be advantageous
to design LCM variants acting on slow inactivation that
are not transported, thus overcoming both candidate mech-
anisms of pharmacoresistance.
Taken together, these results show that LCM exhibits
maintained efficacy in chronic epilepsy, in contrast to con-
ventional use-dependent Na+ channel blockers such as
CBZ. They also establish that development of compounds
targeting slow inactivation may be a promising strategy to
overcome target mechanisms of pharmacoresistance.
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Supplementary Fig. 1: LCM effects on recovery from slow inactivation of Na+ channels in 
human dentate gyrus granule cells. A. Voltage step protocol used to analyse recovery of Na+ 
channels from slow inactivation. Starting 1 second after the conditioning pulse, test pulses (15 
ms) at 3 second intervals were used for determining the time course of recovery from slow 
inactivation. B. Representative examples for recovery from slow inactivation in control and 
pilocarpine-treated rats after 30 second conditioning pulses C. Equivalent example traces 
from a human granule cell.  
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Supplementary Fig. 2: Evaluation of the stability of Na+ current slow inactivation voltage-
dependence under control conditions. A. Voltage protocol used (identical to Fig. 4). B. Slow 
inactivation. All recording parameters were identical to the recordings with LCM. ACSF was 
used for 'control', 'washin' and 'washout' conditions (1st, 2nd and 3rd ACSF). These time-
matched control recordings were performed in sham-control (n=7 for -110 to -50 mV; n=6 for 
-30 mV) and pilocarpine-treated (post-SE) animals (n=3 and 1, respectively). C. Analysis of 
the effect of applying ACSF without LCM. ACSF application had no significant effects. 
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Age at 
surgery Gender 
No 
cells 
Type of 
recording 
Part of 
Figure Type of surgery Pathology 
Treated 
with LCM 
Current 
medication 
Past 
medication 
39 m 3 CC 5, 6 sel. AH left AHS left no VPA, LEV 
CBZ, PB/PRM, 
LTG 
8 f 1 CC 5 sel. AH left AHS left no LTG, LEV same 
55 f 1 CC 5, 6 sel. AH right AHS right no LEV, ESL OXC, TPM 
33 f 2 CC 5, 6 sel. AH left AHS left yes LEV, LCM 
CBZ, OXC, LTG, 
TPM, ZON 
24 m 1 CC 5, 6 sel. AH right Moderate astrogliosis  yes LEV, LCM CBZ 
29 m 1 CC 5, 6 
Lesionectomy & sel. 
AH left 
Developmental malformation 
left no LEV, OXC CBZ 
47 m 1 VC 1-3 
Lesionectomy & sel. 
AH right Cavernoma right no LEV, PGB same 
36 m 1 VC 1-3 sel. AH left AHS left no 
LTG, LEV, 
BZO CBZ 
27 m 1 VC 1-3 sel. AH right unclear yes ESL, LEV LTG, LCM 
43 f 4 VC 1-3 sel. AH left AHS left yes LCM, TPM CBZ, VPA, LTG 
17 f 1 VC 1-3 
temp. pole resection 
& AH right 
temp. pole loss of grey-white 
matter differentiation & AHS r yes LTG, ZON OXC, LEV, LCM 
22 f 1 VC 1-3, S1 sel. AH left AHS left yes LEV, OXC LCM 
37 f 1 VC 1, 4 sel. AH right AHS right no OXC LTG, LEV 
64 m 2 VC 1, 4 sel. AH left AHS left yes TPM, LEV 
CBZ, OXC, VPA, 
LTG, ZON, LCM 
47 f 2 VC 1, 4 sel. AH left AHS left no 
CBZ, LEV, 
ZON same 
45 f 1 VC 1, 4 sel. AH left AHS left no 
LTG, CLB, 
LEV same 
 
 
Supplementary Table 1: Patients with refractory TLE  Sel. AH, selective amygdalohippocampectomy; AHS, Ammon’s horn sclerosis; VPA, 
valproic acid; LEV, levetiracetam; CBZ, carbamazepine; PB, phenobarbital; PRM, primidone; LTG, lamotrigine; ESL, eslicarbazepine; LCM, 
lacosamide; OXC, oxcarbazepine; TPM, topiramate; ZNS, zonisamide; PGB, pregabalin; BZO, oxazepine; CLB, clobazam; 
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 Sham control 
(n=17) 
Post-SE 
(n=19) 
Human epilepsy 
(n=9) 
ACSF (mean of baseline and wash) 
RMP (mV) -70.5 ± 1.2 -68.6 ± 0.8 -66.8 ± 1.4 
Rm (M) 211.6 ± 16.9 175.3 ± 9.5 109.3 ± 13.9 
VPeak [mV] 21.6 ± 2.9 21.4 ± 1.9 25.4 ± 2.5 
VThr [mV] -57.1 ± 1.4 -51.6 ± 2.1 -52.4 ± 1.7 
Width [ms] 0.88 ± 0.02 0.86 ± 0.03 0.94 ± 0.04 
Max. slope [V/s] 274 ± 17 251 ± 13 240 ± 10 
100 µM lacosamide 
RMP (mV) -70.0 ± 1.3 -68.3 ± 0.8 -67.0 ± 1.4 
Rm (M) 221.7 ± 22.6 190.3 ± 11.8 117.8 ± 20.5 
VPeak [mV] 19.6 ± 3.6 20.6 ± 2.6 23.0 ± 2.7 
VThr [mV] -58.6 ± 1.4 -51.9 ± 1.8 -52.5 ± 1.3 
Width [ms] 0.87 ± 0.03 0.85 ± 0.03 0.92 ± 0.05 
Max. slope [V/s] 263 ± 18 246 ± 15 234 ± 18 
 
Supplementary Table 2: Passive membrane and action potential properties of dentate gyrus 
granule neurons in control and epileptic animals, as well as epilepsy patients, in the absence 
and presence of 100 µM LCM. RMP: resting membrane potential, Rm: membrane resistance, 
VPeak : peak of action potentials, VThr: action potential threshold, Width: action potential width 
halfway between threshold and peak potential. 
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 Group LCM Interaction 
RMP (mV) 
F(2,41)=1.847 
p=0.1707 
F(2,41)=0.337 
p=0.5649 
F(1,41)=3.328 
p=0.7223 
Rm (M) 
F(2,41)=8.559 
p=0.0008* 
F(2,41)=1.829 
p=0.1837 
F(1,41)=0.064 
p=0.9383 
VPeak [mV] 
F(2,42)=0.326 
p=0.7235 
F(2,42)=0.374 
p=0.6901 
F(1,42)=3.910 
p=0.0546 
VThreshold [mV] 
F(2,42)=0.796 
p=0.4577 
F(2,42)=4.068 
p=0.0243 
F(1,42)=1.577 
p=0.2161 
Width [ms] 
F(2,42)=0.030 
p=0.9707 
F(2,42)=1.264 
p=0.2930 
F(1,42)=0.648 
p=0.4255 
Max. slope [V/s] 
F(2,42)=0.108 
p=0.8977 
F(2,42)=0.9593 
p=0.3914 
F(1,42)=1.160 
p=0.2876 
 
Supplementary Table 3: Statistics for supplementary table 2. Two-way ANOVA (Sham vs 
Post-SE vs Human and Base&Wash vs LCM). * Tukey's multiple comparisons test yielded 
for sham control vs. post-SE: p=0.2010, for sham control vs. human epilepsy: p=0.0005, and 
for post-SE vs. human epilepsy: p=0.0194.  
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 Sham control Post-SE Human epilepsy 
RMP (mV) 
t=1.7199, df=16 
p=0.4820 
t=0.9292, df=18 
p=0.3651 
t=0.5242, df=7 
p=0.6163 
Rm (M) 
t=0.8412, df=16 
p=0.4126 
t=1.111, df=18 
p=0.2812 
t=0.884, df=7 
p=0.4060 
VPeak [mV] 
t=1.411, df=16 
p=0.1773 
t=0.7048, df=18 
p=0.4899 
t=1.182, df=8 
p=0.2711 
VThreshold [mV] 
t=1.463, df=16 
p=0.1629 
t=0.5591, df=18 
p=0.5830 
t=0.1324, df=8 
p=0.8979 
Width [ms] 
t=0.569, df=16 
p=0.5773 
t=0.6346, df=18 
p=0.5337 
t=0.3075 df=8 
p=0.7663 
Max. slope [V/s] 
t=1.130, df=16 
p=0.2752 
t=0.4238, df=18 
p=0.6767 
t=0.4708, df=8 
p=0.6503 
 
Supplementary Table 4: Statistics for supplementary table 2. Two-tailed paired t-tests 
(Base&Wash vs LCM). Bonferroni correction for multiple tests yielded  = 0.05/18 = 0.0028.  
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3.3 Summary
A loss or reduction of use-dependent block by conventional sodium channel-acting
AEDs has been suggested as an underlying mechanism of pharmacoresistance both
in human and experimental epilepsy (Remy et al., 2003a,b). For the third gener-
ation sodium channel blocker LCM selective enhancement of the slow inactivation
of VGSCs was demonstrated as a novel and unique mechanism of action (Errington
et al., 2008; Sheets et al., 2008). A resulting blockade of action potentials emerging
during pathological high-frequency firing was considered advantageous over bind-
ing to and stabilizing open or fast inactivated channels during pathologic but also
physiologic activity as other sodium channel blockers preferentially do (Beyreuther
et al., 2007; Rogawski et al., 2015). Since this mechanism of action was unique to
LCM and distinguished it from all other sodium channel blockers available at that
time, the purpose of the present publication was to determine whether LCM might
overcome aforementioned mechanism of pharmacoresistance.
Therefore, we determined the effects of LCM on the voltage dependence of VGSC
activation and fast inactivation, the recovery from fast inactivation, entry, recovery,
and voltage dependence of VGSC slow inactivation and on repetitive action poten-
tial firing in dentate granule neurons. To check for alterations in LCM efficacy in
chronic epilepsy, effect sizes observed in control cells and epileptic cells were com-
pared. Voltage-clamp recordings in isolated DGCs revealed that LCM induces small
hyperpolarizing shifts of the voltage dependence of the steady-state fast inactivation
without affecting the activation of VGSCs. Likewise, recovery from fast inactivation
remained largely unaffected. Similar to previous studies in cultured neuroblastoma
cells, much stronger voltage-dependent effects of LCM were observed on the entry of
slow inactivation without affecting its recovery. LCM shifted the voltage dependence
of slow inactivation to more hyperpolarized potentials, indicated by a reversible re-
duction of sodium current amplitudes. These effects translated into an inhibition of
repetitive action potential firing building up over multiple seconds of depolarization.
Further analyses revealed that the blockade of repetitive firing was accompanied by
systematic changes in action potential waveform. The magnitude of all observed
LCM effects were not significantly different between DGCs of nonepileptic rats,
epileptic rats and TLE patiens which implies maintained drug efficacy.
Taken together, LCM exerts strong effects on the voltage dependence of slow
inactivation in DGCs as it was previously shown for cultured neuroblastoma cells.
These effects manifest as inhibition of action potential firing during prolonged de-
polarizations and importantly are maintained under chronic epileptic conditions.
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4 Conclusion
Voltage-gated sodium channels (VGSCs) are critically involved in the generation of
action potentials (APs) and repetitive firing under physiological conditions but also
during epileptic seizures. Older and commonly used antiepileptic drugs (AEDs) such
as carbamazepine (CBZ) exert their anticonvulsant action by slowing the recovery
from fast inactivation of sodium channels. Due to higher affinity for fast-inactivated
sodium channels, inhibition of VGSCs by CBZ is more effective during depolarization
and repetitive AP firing. In animal models of chronic epilepsy and tissue resected
from patients with chronic epilepsy, however, a loss of efficacy of CBZ was reported
(Remy et al., 2003a).
Another, yet different, mechanism of sodium channel inactivation is slow inac-
tivation. Lacosamide (LCM) and eslicarbazepine acetate (via its active metabolite
eslicarbazepine; S-Lic) are the first anticonvulsants described to modulate sodium
channel slow inactivation (Errington et al., 2008; Hebeisen et al., 2015). This raised
the question whether these compounds with a mode of action distinct from classical
use-dependent blockers maintain efficacy in chronic epileptic dentate granule cells
(Doeser et al., 2014a; Holtkamp et al., 2018, 2017). Both substances exert their
main effects by shifting the voltage dependence of sodium channel slow inactivation
in a hyperpolarizing direction, resulting in reduced sodium current amplitudes and
reduced AP firing. Interestingly, maintained efficacy in chronic epileptic tissue was
found for both compounds.
One of the important questions that consequently arise is how minimal changes
in the molecular structure of a drug (in the example of CBZ and S-Lic) can cause
a multitude of critical changes involving its mechanism or kinetics of action, its
specificity for certain target isoforms or its implication for pharmaocoresistance.
Interestingly, these effects seem to occur in an all-or-nothing fashion and not on a
gradual scale. Likewise, it would be interesting to know how the structurally dis-
similar compounds S-Lic and LCM exert almost identical effects on slow inactivation
processes. A recent modeling study proposed a common pharmacophore for many
sodium channel acting drugs, however this study fails to explain potential differences
regarding slow and fast inactivation or pharmacoresistance (Tikhonov and Zhorov,
2017). Recent advances in the identification of high-resolution structures of target
molecules provide the basis for ongoing studies connecting structure, function and
drug-target interactions (Shen et al., 2017). Having highlighted the importance
of slow inactivation-targeting drugs, future studies will likely address these open
questions.
Not only drug specificity for different target isoforms but also distinct effects on
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certain cell types are of paramount interest in translating findings from a single-cell
level to a network level or even the whole brain. Previous studies already showed
that CBZ effects can not only differ between hippocampal pyramidal neurons and
dentate granule cells but also between principal cells and interneurons (Pothmann
et al., 2014; Remy et al., 2003a; Schaub et al., 2007). Ongoing and future studies
will likely also clarify the role of novel AEDs on interneurons and neuronal networks.
Since both, LCM and S-Lic seem to overcome drug resistance on a cellular level,
it may be worthwhile to continue developing and researching novel, optimized com-
pounds that target slow inactivation. Especially in the light of growing possibilities
and importance of tailored or personalized medicines it may be most helpful to de-
velop a broad spectrum of drugs that may be selective to single channel isoforms or
very narrow voltage ranges only. Finally, due to the different mode of action of clas-
sical use-dependent sodium channel blockers and novel slow inactivation-targeting
anticonvulsants, it may prove useful in clinical use to combine these types of drugs
despite acting on the same molecular target.
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